Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)

ABSTRACT

The present invention relates to compounds of formula (I)  
                 
 
     wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a division of U.S. application Ser. No.09/419,864, filed Oct. 19, 1999, now U.S. Pat. No. 6,248,781, which inturn claims priority under 35 U.S.C. 119 of U.S. provisional applicationNo. 60/106,645 filed Nov. 2, 1998 and Danish application no. PA 199801356 filed Oct. 21, 1998, the contents of each of which are fullyincorporated herein by reference.

FIELD OF INVENTION

[0002] The present invention relates to novel compounds, pharmaceuticalcompositions containing them, methods for preparing the compounds andtheir use as medicaments. More specifically, compounds of the inventioncan be utilized in the treatment of conditions mediated by nuclearreceptors, in particular the Peroxisome Proliferator-Activated Receptors(PPAR). The present compounds reduce blood glucose and triglyceridelevels and are accordingly useful for the treatment of ailments anddisorders such as diabetes and obesity.

[0003] The present invention also relates to a process for thepreparation of the above said novel compounds, their derivatives, theiranalogs, their tautomeric forms, their stereoisomers, their polymorphs,their pharmaceutically acceptable salts, pharmaceutically acceptablesolvates and pharmaceutical compositions containing them.

[0004] The compounds are useful for the treatment and/or prophylaxis ofinsulin resistance (type 2 diabetes), impaired glucose tolerance,dyslipidemia, disorders related to Syndrome X such as hypertension,obesity, insulin resistance, hyperglycemia, atherosclerosis,hyperlipidemia, coronary artery disease and other cardiovasculardisorders. The compounds of the present invention are also useful forthe treatment of certain renal diseases including glomerulonephritis,glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis.These compounds may also be useful for improving cognitive functions indementia, treating diabetic complications, psoriasis, polycystic ovariansyndrome (PCOS) and prevention and treatment of bone loss, e.g.osteoporosis.

BACKGROUND OF THE INVENTION

[0005] Coronary artery disease (CAD) is the major cause of death in type2 diabetic and metabolic syndrome patients (i.e. patients that fallwithin the ‘deadly quartet’ category of impaired glucose tolerance,insulin resistance, hypertriglyceridemia and/or obesity).

[0006] The hypolipidemic fibrates and antidiabetic thiazolidinedionesseparately display moderately effective triglyceride-lowering activitiesalthough they are neither potent nor efficacious enough to be a singletherapy of choice for the dyslipidemia often observed in type 2 diabeticor metabolic syndrome patients. The thiazolidinediones also potentlylower circulating glucose levels of type 2 diabetic animal models andhumans. However, the fibrate class of compounds are without beneficialeffects on glycemia. Studies on the molecular actions of these compoundsindicate that thiazolidinediones and fibrates exert their action byactivating distinct transcription factors of the peroxisome proliferatoractivated receptor (PPAR) family, resulting in increased and decreasedexpression of specific enzymes and apolipoproteins respectively, bothkey-players in regulation of plasma triglyceride content. Fibrates, onthe one hand, are PPARα activators, acting primarily in the liver.Thiazolidinediones, on the other hand, are high affinity ligands forPPARγ acting primarily on adipose tissue.

[0007] Adipose tissue plays a central role in lipid homeostasis and themaintenance of energy balance in vertebrates. Adipocytes store energy inthe form of triglycerides during periods of nutritional affluence andrelease it in the form of free fatty acids at times of nutritionaldeprivation. The development of white adipose tissue is the result of acontinuous differentiation process throughout life. Much evidence pointsto the central role of PPARγ activation in initiating and regulatingthis cell differentiation. Several highly specialised proteins areinduced during adipocyte differentiation, most of them being involved inlipid storage and metabolism. The exact link from activation of PPARγ tochanges in glucose metabolism, most notably a decrease in insulinresistance in muscle, has not yet been clarified. A possible link is viafree fatty acids such that activation of PPARγ induces LipoproteinLipase (LPL), Fatty Acid Transport Protein (FATP) and Acyl-CoASynthetase (ACS) in adipose tissue but not in muscle tissue. This, inturn, reduces the concentration of free fatty acids in plasmadramatically, and due to substrate competition at the cellular level,skeletal muscle and other tissues with high metabolic rates eventuallyswitch from fatty acid oxidation to glucose oxidation with decreasedinsulin resistance as a consequence.

[0008] PPARα is involved in stimulating β-oxidation of fatty acids. Inrodents, a PPARα-mediated change in the expression of genes involved infatty acid metabolism lies at the basis of the phenomenon of peroxisomeproliferation, a pleiotropic cellular response, mainly limited to liverand kidney and which can lead to hepatocarcinogenesis in rodents. Thephenomenon of peroxisome proliferation is not seen in man. In additionto its role in peroxisome proliferation in rodents, PPARα is alsoinvolved in the control of HDL cholesterol levels in rodents and humans.This effect is, at least partially, based on a PPARα-mediatedtranscriptional regulation of the major HDL apolipoproteins, apo A-I andapo A-II. The hypotriglyceridemic action of fibrates and fatty acidsalso involves PPARα and can be summarised as follows: (I) an increasedlipolysis and clearance of remnant particles, due to changes inlipoprotein lipase and apo C-III levels, (II) a stimulation of cellularfatty acid uptake and their subsequent conversion to acyl-CoAderivatives by the induction of fatty acid binding protein and acyl-CoAsynthase, (III) an induction of fatty acid b-oxidation pathways, (IV) areduction in fatty acid and triglyceride synthesis, and finally (V) adecrease in VLDL production. Hence, both enhanced catabolism oftriglyceride-rich particles as well as reduced secretion of VLDLparticles constitutes mechanisms that contribute to the hypolipidemiceffect of fibrates.

[0009] A number of compounds have been reported to be useful in thetreatment of hyperglycemia, hyperlipidemia and hypercholesterolemia(U.S. Pat. No. 5,306,726, PCT Publications nos. WO91/19702, WO 95/03038,WO 96/04260, WO 94/13650, WO 94/01420, WO 97/36579, WO 97/25042, WO95/17394, WO 99/08501, WO 99/19313 and WO 99/16758).

SUMMARY OF THE INVENTION

[0010] It seems more and more apparent that glucose lowering as a singleapproach does not overcome the macrovascular complications associatedwith type 2 diabetes and metabolic syndrome. Novel treatments of type 2diabetes and metabolic syndrome must therefore aim at lowering both theovert hypertriglyceridaemia associated with these syndromes as well asalleviation of hyperglycemia.

[0011] The clinical activity of fibrates and thiazolidinedionesindicates that research for compounds displaying combined PPAR α andPPAR γ activation should lead to the discovery of efficacious glucoseand triglyceride lowering drugs that have great potential in thetreatment of type 2 diabetes and the metabolic syndrome (i.e. impairedglucose tolerance, insulin resistance, hypertriglyceridemia and/orobesity).

DETAILED DESCRIPTION OF THE INVENTION

[0012] Accordingly, the present invention relates to compounds offormula (Ia):

[0013] wherein R¹, R², R³, and R⁴ independently of each other representhydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, orC₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂alkoxy,aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl,heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy,hydroxyC₁₋₁₂alkyl, amino, acylamino, C₁₋₁₂alkyl-amino, arylamino,aralkylamino, aminoC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl,aralkoxycarbonyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl,aralkoxyC₁₋₁₂alkyl, C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,—COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹² independently of each other areselected from hydroxy, halogen, perhalomethyl, C₁₋₆-alkoxy or aminooptionally substituted with one or more C₁₋₆alkyl, perhalomethyl oraryl; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano;

[0014] or R¹ and R², R² and R³ and/or R³ and R⁴, together with thecarbon atoms to which they are attached, may form a cyclic ringcontaining from 5 to 7 carbon atoms optionally substituted with one ormore C₁₋₆alkyl;

[0015] ring A represents a 5-6 membered cyclic ring, optionallysubstituted with one or more halogen, perhalomethyl, hydroxy, nitro,cyano, formyl, or C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl,C₂₋₁₂-alkynyl, C₁₋₁₂alkoxy, aryl, aryloxy, aralkyl, aralkoxy,heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy,acyl, acyloxy, hydroxyC₁₋₁₂alkyl, amino, acylamino, C₁₋₁₂alkyl-amino,arylamino, aralkylamino, aminoC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonyl,aryloxycarbonyl, aralkoxycarbonyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl,aryloxyC₁₋₁₂alkyl, aralkoxyC₁₋₁₂alkyl, C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,—COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹² independently of each other areselected from hydroxy, halogen, perhalomethyl, C₁₋₆-alkoxy or aminooptionally substituted with one or more C₁₋₆alkyl, perhalomethyl oraryl; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano;

[0016] X is a valence bond, —(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—,—O—(CHR⁹)—, —S—(CHR⁹)—, —(NR⁹)—CH₂—, —(CHR⁹)—CH═CH—, —(CHR⁹)—CH₂—CH₂—,—(C═O)—, —O—CH₂—O—, —(NR⁹)—S(O₂)—, —(NR⁹)—, —CH═(CR⁹)—, —(CO)—(CHR⁹)—,—CH₂—(SO)—, —S—, —(SO)—, —(SO₂)—, —CH₂—(SO₂)—, —CH₂—O—CH₂—, wherein R⁹is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C₁₋₁₂alkyl,C₁₋₁₂alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl,heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy,hydroxyalkyl, amino, acylamino, C₁₋₁₂alkyl-amino, arylamino,aralkylamino, aminoC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl,aralkoxycarbonyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl,aralkoxyC₁₋₁₂alkyl, C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,—COR¹³, or —SO₂R¹⁴, wherein R¹³ and R¹⁴ independently of each other areselected from hydroxy, halogen, C₁₋₆alkoxy, amino optionally substitutedwith one or more C₁₋₆alkyl, perhalomethyl or aryl;

[0017] Z is —CH₂—, —O—, —S—, >SO_(2,), >NR¹⁵, wherein R¹⁵ is hydrogen,halogen, hydroxy, nitro, cyano, formyl, C₁₋₁₂alkyl, C₁₋₁₂alkoxy, aryl,aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino,acylamino, C₁₋₁₂alkyl-amino, arylamino, aralkylamino, aminoC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl, aralkoxyC₁₋₁₂alkyl,C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonylamino,aryloxycarbonylamino, aralkoxycarbonylamino, —COR¹⁶, or —SO₂R¹⁷, whereinR¹⁶ and R¹⁷ independently of each other are selected from hydroxy,halogen, C₁₋₆alkoxy, amino optionally substituted with one or moreC₁₋₆-alkyl, perhalomethyl or aryl;

[0018] Q is —O—, —S—, >NR¹⁸ wherein R¹⁸ is hydrogen or C₁₋₆-alkyl;

[0019] Ar represents arylene, heteroarylene, or a divalent heterocyclicgroup optionally substituted with one or more C₁₋₆-alkyl or aryl;

[0020] R⁵ represents hydrogen, hydroxy, halogen, C₁₋₁₂alkoxy,C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl or aralkyl;optionally substituted with one or more halogen, perhalomethyl, hydroxy,nitro or cyano; or R⁵ forms a bond together with R⁶;

[0021] R⁶ represents hydrogen, hydroxy, halogen, C₁₋₁₂alkoxy,C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, acyl oraralkyl; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano; or R⁶ forms a bond together with R⁵;

[0022] R⁷ represents hydrogen, C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl,C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, aryl, aralkyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl, C₁₋₁₂alkylaminocarbonyl,arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkylgroups; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano;

[0023] R⁸ represents hydrogen, C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl,C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl orheteroaralkyl groups; optionally substituted with one or more halogen,perhalomethyl, hydroxy, nitro or cyano;

[0024] Y represents oxygen, sulphur or NR¹⁰, where R¹⁰ representshydrogen, C₁₋₁₂alkyl, aryl, hydroxyC₁₋₁₂alkyl or aralkyl groups or whenY is NR¹⁰, R⁸ and R¹⁰ may form a 5 or 6 membered nitrogen containingring, optionally substituted with one or more C₁₋₆alkyl;

[0025] n is an integer ranging from 1 to 4;

[0026] or a pharmaceutically acceptable salt thereof.

[0027] In a preferred embodiment, the present invention is concernedwith compounds of formula I wherein R¹, R², R³, and R⁴ independently ofeach other represent hydrogen, halogen, perhalomethyl, hydroxy, cyano,or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy,aryl, aryloxy, aralkyl, aralkoxy, beterocyclyl, heteroaryl,heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy,hydroxyC₁₋₇alkyl, amino, acylamino, C₁₋₇alkyl-amino, arylamino,aralkylamino, aminoC₁₋₇alkyl, C₁₋₇alkoxycarbonyl, aryloxycarbonyl,aralkoxycarbonyl, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl,aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio, thioC₁₋₇alkyl,C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,—COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹² independently of each other areselected from hydroxy, perhalomethyl, C₁₋₆alkoxy or amino optionallysubstituted with one or more C₁₋₆-alkyl, perhalomethyl or aryl;optionally substituted with one or more halogen, perhalomethyl, hydroxy,nitro or cyano; or R¹ and R², R² and R³ and/or R³ and R⁴ may form acyclic ring containing from 5 to 7 carbon atoms optionally substitutedwith one or more C₁₋₆-alkyl.

[0028] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, halogen, perhalomethyl,hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl,C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl, aralkoxy,heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy,acyl, hydroxyC₁₋₇alkyl, amino, acylamino, C₁₋₇alkyl-amino, arylamino,aralkylamino, aminoC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl,aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio, thioC₁₋₇alkyl,C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino or aralkoxycarbonylamino.

[0029] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, halogen, perhalomethyl,hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl,C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl, aralkoxy, acyl,hydroxyC₁₋₇alkyl, amino, C₁₋₇alkyl-amino, arylamino, aralkylamino,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alky orC₁₋₇alkylthio.

[0030] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, halogen, perhalomethyl,or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl,hydroxyC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl oraralkoxyC₁₋₇alkyl.

[0031] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, halogen or C₁₋₇alkyl.

[0032] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, chlorine or methyl.

[0033] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein ring A represents a 5-6membered cyclic ring, optionally substituted with one or more halogen,perhalomethyl, hydroxy, cyano or C₁₋₇alkyl, C₄₋₇-alkenynyl,C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl,aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy,heteroaralkoxy, acyl, acyloxy, hydroxyC₁₋₇alkyl, amino, acylamino,C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio,thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino,aralkoxycarbonylamino, —COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹²independently of each other are selected from hydroxy, perhalomethyl,C₁₋₆-alkoxy or amino optionally substituted with one or more C₁₋₆alkyl,perhalomethyl or aryl; optionally substituted with one or more halogen,perhalomethyl, hydroxy or cyano.

[0034] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein ring A represents a 5-6membered cyclic ring, optionally substituted with one or more halogen,perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl,C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl,aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy,heteroaralkoxy, acyl, hydroxyC₁₋₇alkyl, amino, acylamino,C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio,thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino oraralkoxycarbonylamino.

[0035] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein ring A represents a 5-6membered cyclic ring, optionally substituted with one or more halogen,perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl,C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl,aralkoxy, acyl, hydroxyC₁₋₇alkyl, amino, C₁₋₇alkyl-amino, arylamino,aralkylamino, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkylor C₁₋₇alkylthio.

[0036] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein ring A represents a 5-6membered cyclic ring, optionally substituted with one or more halogen,perhalomethyl or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl,C₁₋₇alkoxy, aryl, aralkyl, hydroxyC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl,aryloxyC₁₋₇alkyl or aralkoxyC₁₋₇alkyl.

[0037] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein ring A represents a 5-6membered cyclic ring, optionally substituted with one or more chlorineor methyl groups.

[0038] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is a valence bond,—(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—, —O—(CHR⁹)—, —S—(CHR⁹)—,—(NR⁹)—CH₂—, —(CHR⁹)—CH═CH—, —(CHR⁹)—CH₂—CH₂—, —(C═O)—, —O—CH₂—O—,—(NR⁹)—S(O₂)—, —(NR⁹)—, —CH═(CR⁹)—, —(CO)—(CHR⁹)—, —CH₂—(SO)—, —S—,—(SO)—, —(SO₂)—, —CH₂—(SO₂)— or —CH₂—O—CH₂—, wherein R⁹ is hydrogen,halogen, hydroxy, C₁₋₇alkyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl,aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy,heteroaralkoxy, hydroxyalkyl, amino, acylamino, C₁₋₇alkyl-amino,arylamino, aralkylamino, aminoC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₁₂alkyl,aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₁₂alkylthio, thioC₁₋₇alkyl,C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino or aralkoxycarbonylamino.

[0039] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is a valence bond,—(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—, —O—(CHR⁹)—, —S—(CHR⁹)—,—(NR⁹)—CH₂—, —(CHR⁹)—CH═CH—, —(CHR⁹)—CH₂—CH₂—, —(C═O)—, —O—CH₂—O—,—(NR⁹)—S(O₂)—, —(NR⁹)—, —CH═(CR⁹)—, —(CO)—(CHR⁹)—, —CH₂—(SO)—, —S—,—(SO)—, —(SO₂)—, —CH₂—(SO₂)— or —CH₂—O—CH₂—, wherein R⁹ is hydrogen,halogen, hydroxy, C₁₋₇alkyl, aryl, aralkyl, C₁₋₇alkoxyC₁₋₁₂alkyl,aryloxyC₁₋₇alkyl or aralkoxyC₁₋₇alkyl.

[0040] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is a valence bond,—(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—, —O—(CHR⁹)—, —S—(CHR⁹)—,—(NR⁹)—CH₂—, —(CHR⁹)—CH═CH—, —(CHR⁹)—CH₂—CH₂—, —(C═O)—, —O—CH₂—O—,—(NR⁹)—S(O₂)—, —(NR⁹)—, —CH═(CR⁹)—, —(CO)—(CHR⁹)—, —CH₂—(SO)—, —S—,—(SO)—, —(SO₂)—, —CH₂—(SO₂)— or —CH₂—O—CH₂—, wherein R⁹ is hydrogen.

[0041] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is a valence bond,—(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—, —O—(CHR⁹)—, —S—(CHR⁹)—,—(NR⁹)—CH₂—, —O—CH₂—O—, —(NR⁹)—, —S—, —(SO)— or —CH₂—O—CH₂—, wherein R⁹is hydrogen.

[0042] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is a valence bond,—(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—, —O—(CHR⁹)—, —S—(CHR⁹)—,—(NR⁹)—CH₂—, —O—CH₂—O—, —(NR⁹)—, —S— or —CH₂—O—CH₂—, wherein R⁹ ishydrogen.

[0043] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is a valence bond,—(CHR⁹)—, —(CHR⁹)—CH₂—, —CH═CH—, —O—, —O—(CHR⁹)—, —S—(CHR⁹)—, —O—CH₂—O—or —S—, wherein R⁹ is hydrogen.

[0044] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Z is —CH₂—, —O—, —S—,>NR¹⁵, wherein R¹⁵ is hydrogen, C₁₋₁₂alkyl, C₁₋₇alkoxy, aralkyl,aralkoxy, hydroxyalkyl, aminoC₁₋₇alkyl, C₁₋₁₂alkoxyC₁₋₇alkyl,aryloxyC₁₋₇alkyl or aralkoxyC₁₋₇alkyl.

[0045] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Z is —CH₂—, —O—, —S— or>NR¹⁵, wherein R¹⁵ is hydrogen.

[0046] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Z is —O—.

[0047] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Q is —O—, —S— or >NR¹⁸wherein R¹⁸ is hydrogen or methyl.

[0048] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Q is —O— or >NR¹⁸ whereinR¹⁸ is methyl.

[0049] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Ar represents aryleneoptionally substituted with one or more C₁₋₆-alkyl or aryl.

[0050] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Ar represents phenyl.

[0051] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁵ represents hydrogen,hydroxy, halogen, C₁₋₇alkoxy, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl,C₂₋₇-alkynyl or aralkyl, or R⁵ forms a bond together with R⁶.

[0052] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁵ represents hydrogen orR⁵ forms a bond together with R⁶.

[0053] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁵ represents hydrogen,hydroxy, halogen, C₁₋₇alkoxy, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl,C₂₋₇-alkynyl or aralkyl, or R⁵ forms a bond together with R⁶.

[0054] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁵ represents hydrogen orR⁵ forms a bond together with R⁶.

[0055] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁷ represents hydrogen,C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl,C₁₋₇alkoxyC₁₋₇alkyl, C₁₋₇alkoxycarbonyl, aryloxycarbonyl,C₁₋₇alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl,heteroaryl or heteroaralkyl groups.

[0056] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁷ represents hydrogen,C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl or C₂₋₇-alkynyl.

[0057] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁷ represents C₁₋₂alkyl.

[0058] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁸ represents hydrogen,C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl,heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substitutedwith one or more halogen, perhalomethyl, hydroxy, nitro or cyano.

[0059] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁸ represents hydrogen,C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl or aralkyl.

[0060] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁸ represents hydrogen orC₁₋₂alkyl.

[0061] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Y represents oxygen,sulphur or NR¹⁰, where R¹⁰ represents hydrogen, C₁₋₇alkyl, aryl,hydroxyC₁₋₇alkyl or aralkyl groups.

[0062] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Y represents oxygen.

[0063] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein n is an integer rangingfrom 2 to 3.

[0064] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein A is benzo.

[0065] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein A is a five membered ringcontaining S.

[0066] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is —(CHR⁹)—CH₂—, whereinR⁹ is H.

[0067] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is —O—(CHR⁹)—, whereinR⁹ is H.

[0068] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is —S—(CHR⁹)—, whereinR⁹ is H.

[0069] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein X is —O—CH₂—O—.

[0070] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Q is —O—.

[0071] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Q is —S—.

[0072] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Q is >NR¹⁸, wherein R¹⁸ isC₁₋₆-alkyl, preferably methyl.

[0073] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Z is —O—.

[0074] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein n is 2.

[0075] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Q is —O—.

[0076] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein Ar is phenylene.

[0077] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁵ is H.

[0078] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁶ is H.

[0079] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁷ is ethyl.

[0080] In another preferred embodiment, the present invention isconcerned with compounds of formula I wherein R⁸ is H.

[0081] Preferred compounds of the invention are:

[0082]2-Ethoxy-3-(4-[2-[2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0083]2-Ethoxy-3-(4-[2-[2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0084]2-Ethoxy-3-(4-[2-[2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0085]2-Ethoxy-3-(4-[2-[2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0086]2-Ethoxy-3-(4-[2-[2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0087]2-Ethoxy-3-(4-[2-[2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0088]2-Ethoxy-3-(4-[2-[3-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0089]2-Ethoxy-3-(4-[2-[3-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0090]2-Ethoxy-3-(4-[2-[3-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0091]2-Ethoxy-3-(4-[2-[3-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0092]2-Ethoxy-3-(4-[2-[3-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0093]2-Ethoxy-3-(4-[2-[3-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0094]3-(4-[2-[2,8-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0095]3-(4-[2-[2,8-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0096]3-(4-[2-[2,8-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0097]3-(4-[2-[2,8-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0098]3-(4-[2-[2,8-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0099]3-(4-[2-[2,8-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0100]3-(4-[2-[2,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0101]3-(4-[2-[2,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0102]3-(4-[2-[2,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0103]3-(4-[2-[2,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0104]3-(4-[2-[2,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0105]3-(4-[2-[2,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0106]3-(4-[2-[3,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0107]3-(4-[2-[3,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0108]3-(4-[2-[3,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0109]3-(4-[2-[3,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0110]3-(4-[2-[3,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0111]3-(4-[2-[3,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0112]2-Ethoxy-3-(4-[2-[7-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0113]2-Ethoxy-3-(4-[2-[7-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0114]2-Ethoxy-3-(4-[2-[7-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0115]2-Ethoxy-3-(4-[2-[7-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0116]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0117]2-Ethoxy-3-(4-[2-[7-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0118]2-Ethoxy-3-(4-[2-[7-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0119]2-Ethoxy-3-(4-[2-[7-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0120]2-Ethoxy-3-(4-[2-[7-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0121]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0122]2-Ethoxy-3-(4-[2-[7-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0123]2-Ethoxy-3-(4-[2-[7-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0124]2-Ethoxy-3-(4-[2-[7-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0125]2-Ethoxy-3-(4-[2-[7-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0126]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0127]2-Ethoxy-3-(4-[2-[7-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0128]2-Ethoxy-3-(4-[2-[7-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0129]2-Ethoxy-3-(4-[2-[7-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0130]2-Ethoxy-3-(4-[2-[7-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0131]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0132]2-Ethoxy-3-(4-[2-[7-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0133]2-Ethoxy-3-(4-[2-[7-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0134]2-Ethoxy-3-(4-[2-[7-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0135]2-Ethoxy-3-(4-[2-[7-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0136]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0137]2-Ethoxy-3-(4-[2-[7-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0138]2-Ethoxy-3-(4-[2-[7-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0139]2-Ethoxy-3-(4-[2-[7-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0140]2-Ethoxy-3-(4-[2-[7-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0141]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0142]2-Ethoxy-3-(4-[2-[8-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0143]2-Ethoxy-3-(4-[2-[8-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0144]2-Ethoxy-3-(4-[2-[8-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0145]2-Ethoxy-3-(4-[2-[8-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0146]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0147]2-Ethoxy-3-(4-[2-[8-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0148]2-Ethoxy-3-(4-[2-[8-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0149]2-Ethoxy-3-(4-[2-[8-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0150]2-Ethoxy-3-(4-[2-[8-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0151]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0152]2-Ethoxy-3-(4-[2-[8-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0153]2-Ethoxy-3-(4-[2-[8-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0154]2-Ethoxy-3-(4-[2-[8-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0155]2-Ethoxy-3-(4-[2-[8-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0156]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0157]2-Ethoxy-3-(4-[2-[8-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0158]2-Ethoxy-3-(4-[2-[8-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0159]2-Ethoxy-3-(4-[2-[8-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0160]2-Ethoxy-3-(4-[2-[8-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0161]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0162]2-Ethoxy-3-(4-[2-[8-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0163]2-Ethoxy-3-(4-[2-[8-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0164]2-Ethoxy-3-(4-[2-[8-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0165]2-Ethoxy-3-(4-[2-[8-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0166]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0167]2-Ethoxy-3-(4-[2-[8-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0168]2-Ethoxy-3-(4-[2-[8-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0169]2-Ethoxy-3-(4-[2-[8-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0170]2-Ethoxy-3-(4-[2-[8-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0171]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0172]2-Ethoxy-3-(4-[2-[2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0173]2-Ethoxy-3-(4-[2-[2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0174]2-Ethoxy-3-(4-[2-[2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0175]2-Ethoxy-3-(4-[2-[2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0176]2-Ethoxy-3-(4-[2-[2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0177]2-Ethoxy-3-(4-[2-[2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0178]2-Ethoxy-3-(4-[2-[3-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0179]2-Ethoxy-3-(4-[2-[3-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0180]2-Ethoxy-3-(4-[2-[3-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0181]2-Ethoxy-3-(4-[2-[3-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0182]2-Ethoxy-3-(4-[2-[3-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0183]2-Ethoxy-3-(4-[2-[3-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0184]3-(4-[2-[2,8-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0185]3-(4-[2-[2,8-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0186]3-(4-[2-[2,8-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0187]3-(4-[2-[2,8-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0188]3-(4-[2-[2,8-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0189]3-(4-[2-[2,8-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0190]3-(4-[2-[2,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0191]3-(4-[2-[2,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0192]3-(4-[2-[2,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0193]3-(4-[2-[2,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0194]3-(4-[2-[2,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0195]3-(4-[2-[2,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0196]3-(4-[2-[3,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0197]3-(4-[2-[3,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0198]3-(4-[2-[3,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0199]3-(4-[2-[3,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0200]3-(4-[2-[3,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0201]3-(4-[2-[3,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0202]2-Ethoxy-3-(4-[2-[7-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0203]2-Ethoxy-3-(4-[2-[7-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0204]2-Ethoxy-3-(4-[2-[7-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0205]2-Ethoxy-3-(4-[2-[7-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0206]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0207]2-Ethoxy-3-(4-[2-[7-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0208]2-Ethoxy-3-(4-[2-[7-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0209]2-Ethoxy-3-(4-[2-[7-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0210]2-Ethoxy-3-(4-[2-[7-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0211]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0212]2-Ethoxy-3-(4-[2-[7-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0213]2-Ethoxy-3-(4-[2-[7-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0214]2-Ethoxy-3-(4-[2-[7-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0215]2-Ethoxy-3-(4-[2-[7-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0216]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0217]2-Ethoxy-3-(4-[2-[7-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0218]2-Ethoxy-3-(4-[2-[7-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0219]2-Ethoxy-3-(4-[2-[7-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0220]2-Ethoxy-3-(4-[2-[7-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0221]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0222]2-Ethoxy-3-(4-[2-[7-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0223]2-Ethoxy-3-(4-[2-[7-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0224]2-Ethoxy-3-(4-[2-[7-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0225]2-Ethoxy-3-(4-[2-[7-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0226]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0227]2-Ethoxy-3-(4-[2-[7-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0228]2-Ethoxy-3-(4-[2-[7-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0229]2-Ethoxy-3-(4-[2-[7-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0230]2-Ethoxy-3-(4-[2-[7-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0231]2-Ethoxy-3-(4-[2-[7-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0232]2-Ethoxy-3-(4-[2-[8-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0233]2-Ethoxy-3-(4-[2-[8-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0234]2-Ethoxy-3-(4-[2-[8-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0235]2-Ethoxy-3-(4-[2-[8-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0236]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0237]2-Ethoxy-3-(4-[2-[8-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0238]2-Ethoxy-3-(4-[2-[8-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0239]2-Ethoxy-3-(4-[2-[8-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0240]2-Ethoxy-3-(4-[2-[8-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0241]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0242]2-Ethoxy-3-(4-[2-[8-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0243]2-Ethoxy-3-(4-[2-[8-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0244]2-Ethoxy-3-(4-[2-[8-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0245]2-Ethoxy-3-(4-[2-[8-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0246]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0247]2-Ethoxy-3-(4-[2-[8-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0248]2-Ethoxy-3-(4-[2-[8-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0249]2-Ethoxy-3-(4-[2-[8-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0250]2-Ethoxy-3-(4-[2-[8-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0251]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0252]2-Ethoxy-3-(4-[2-[8-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0253]2-Ethoxy-3-(4-[2-[8-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0254]2-Ethoxy-3-(4-[2-[8-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0255]2-Ethoxy-3-(4-[2-[8-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0256]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0257]2-Ethoxy-3-(4-[2-[8-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0258]2-Ethoxy-3-(4-[2-[8-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0259]2-Ethoxy-3-(4-[2-[8-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0260]2-Ethoxy-3-(4-[2-[8-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0261]2-Ethoxy-3-(4-[2-[8-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0262]2-Ethoxy-3-(4-[2-[methyl-(2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0263]2-Ethoxy-3-(4-[2-[methyl-(2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0264]2-Ethoxy-3-(4-[2-[methyl-(2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0265]2-Ethoxy-3-(4-[2-[methyl-(2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0266]2-Ethoxy-3-(4-[2-[methyl-(2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0267]2-Ethoxy-3-(4-[2-[methyl-(2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0268]2-Ethoxy-3-(4-[2-[methyl-(3-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0269]2-Ethoxy-3-(4-[2-[methyl-(3-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0270]2-Ethoxy-3-(4-[2-[methyl-(3-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0271]2-Ethoxy-3-(4-[2-[methyl-(3-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0272]2-Ethoxy-3-(4-[2-[methyl-(3-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0273]2-Ethoxy-3-(4-[2-[methyl-(3-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0274]3-(4-[2-[2,8-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0275]3-(4-[2-[2,8-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0276]3-(4-[2-[2,8-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0277]3-(4-[2-[2,8-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0278]3-(4-[2-[2,8-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0279]3-(4-[2-[2,8-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0280]3-(4-[2-[2,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0281]3-(4-[2-[2,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0282]3-(4-[2-[2,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0283]3-(4-[2-[2,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0284]3-(4-[2-[2,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0285]3-(4-[2-[2,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0286]3-(4-[2-[3,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0287]3-(4-[2-[3,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0288]3-(4-[2-[3,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0289]3-(4-[2-[3,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0290]3-(4-[2-[3,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0291]3-(4-[2-[3,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0292]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0293]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0294]2-Ethoxy-3-(4-[2-[methyl-(7-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0295]2-Ethoxy-3-(4-[2-[methyl-(7-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0296]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0297]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0298]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0299]2-Ethoxy-3-(4-[2-[methyl-(7-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0300]2-Ethoxy-3-(4-[2-[methyl-(7-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0301]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0302]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0303]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0304]2-Ethoxy-3-(4-[2-[methyl-(7-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0305]2-Ethoxy-3-(4-[2-[methyl-(7-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0306]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0307]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0308]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0309]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0310]2-Ethoxy-3-(4-[2-[methyl-(7-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0311]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0312]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0313]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0314]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0315]2-Ethoxy-3-(4-[2-[methyl-(7-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0316]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0317]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0318]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0319]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0320]2-Ethoxy-3-(4-[2-[methyl-(7-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0321]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0322]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0323]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0324]2-Ethoxy-3-(4-[2-[methyl-(8-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0325]2-Ethoxy-3-(4-[2-[methyl-(8-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0326]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0327]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0328]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0329]2-Ethoxy-3-(4-[2-[methyl-(8-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0330]2-Ethoxy-3-(4-[2-[methyl-(8-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0331]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0332]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0333]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0334]2-Ethoxy-3-(4-[2-[methyl-(8-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0335]2-Ethoxy-3-(4-[2-[methyl-(8-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0336]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0337]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0338]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0339]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0340]2-Ethoxy-3-(4-[2-[methyl-(8-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0341]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0342]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0343]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0344]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0345]2-Ethoxy-3-(4-[2-[methyl-(8-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0346]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0347]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0348]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0349]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0350]2-Ethoxy-3-(4-[2-[methyl-(8-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0351]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0352]2-Ethoxy-3-(4-[2-[methyl-(2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0353]2-Ethoxy-3-(4-[2-[methyl-(2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0354]2-Ethoxy-3-(4-[2-[methyl-(2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0355]2-Ethoxy-3-(4-[2-[methyl-(2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0356]2-Ethoxy-3-(4-[2-[methyl-(2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0357]2-Ethoxy-3-(4-[2-[methyl-(2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0358]2-Ethoxy-3-(4-[2-[methyl-(3-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]-ethoxy]-phenyl)-propionicacid,

[0359]2-Ethoxy-3-(4-[2-[methyl-(3-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0360]2-Ethoxy-3-(4-[2-[methyl-(3-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0361]2-Ethoxy-3-(4-[2-[methyl-(3-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0362]2-Ethoxy-3-(4-[2-[methyl-(3-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0363]2-Ethoxy-3-(4-[2-[methyl-(3-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0364]3-(4-[2-[2,8-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0365]3-(4-[2-[2,8-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0366]3-(4-[2-[2,8-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0367]3-(4-[2-[2,8-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0368]3-(4-[2-[2,8-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0369]3-(4-[2-[2,8-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0370]3-(4-[2-[2,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0371]3-(4-[2-[2,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0372]3-(4-[2-[2,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0373]3-(4-[2-[2,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0374]3-(4-[2-[2,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0375]3-(4-[2-[2,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0376]3-(4-[2-[3,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0377]3-(4-[2-[3,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0378]3-(4-[2-[3,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0379]3-(4-[2-[3,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0380]3-(4-[2-[3,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0381]3-(4-[2-[3,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0382]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0383]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0384]2-Ethoxy-3-(4-[2-[methyl-(7-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0385]2-Ethoxy-3-(4-[2-[methyl-(7-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0386]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0387]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0388]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0389]2-Ethoxy-3-(4-[2-[methyl-(7-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0390]2-Ethoxy-3-(4-[2-[methyl-(7-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0391]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0392]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0393]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0394]2-Ethoxy-3-(4-[2-[methyl-(7-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0395]2-Ethoxy-3-(4-[2-[methyl-(7-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0396]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0397]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0398]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0399]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0400]2-Ethoxy-3-(4-[2-[methyl-(7-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0401]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0402]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0403]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0404]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0405]2-Ethoxy-3-(4-[2-[methyl-(7-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0406]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0407]2-Ethoxy-3-(4-[2-[methyl-(7-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0408]2-Ethoxy-3-(4-[2-[methyl-(7-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0409]2-Ethoxy-3-(4-[2-[methyl-(7-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0410]2-Ethoxy-3-(4-[2-[methyl-(7-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0411]2-Ethoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0412]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0413]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0414]2-Ethoxy-3-(4-[2-[methyl-(8-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0415]2-Ethoxy-3-(4-[2-[methyl-(8-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0416]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0417]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0418]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0419]2-Ethoxy-3-(4-[2-[methyl-(8-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0420]2-Ethoxy-3-(4-[2-[methyl-(8-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0421]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0422]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0423]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0424]2-Ethoxy-3-(4-[2-[methyl-(8-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0425]2-Ethoxy-3-(4-[2-[methyl-(8-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0426]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0427]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0428]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0429]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0430]2-Ethoxy-3-(4-[2-[methyl-(8-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0431]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0432]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0433]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0434]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0435]2-Ethoxy-3-(4-[2-[methyl-(8-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0436]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0437]2-Ethoxy-3-(4-[2-[methyl-(8-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0438]2-Ethoxy-3-(4-[2-[methyl-(8-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0439]2-Ethoxy-3-(4-[2-[methyl-(8-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0440]2-Ethoxy-3-(4-[2-[methyl-(8-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0441]2-Ethoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0442]2-Methoxy-3-(4-[2-[2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0443]2-Methoxy-3-(4-[2-[2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0444]2-Methoxy-3-(4-[2-[2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0445]2-Methoxy-3-(4-[2-[2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0446]2-Methoxy-3-(4-[2-[2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0447]2-Methoxy-3-(4-[2-[2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0448]2-Methoxy-3-(4-[2-[3-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0449]2-Methoxy-3-(4-[2-[3-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0450]2-Methoxy-3-(4-[2-[3-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0451]2-Methoxy-3-(4-[2-[3-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0452]2-Methoxy-3-(4-[2-[3-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0453]2-Methoxy-3-(4-[2-[3-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0454]3-(4-[2-[2,8-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0455]3-(4-[2-[2,8-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0456]3-(4-[2-[2,8-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0457]3-(4-[2-[2,8-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0458]3-(4-[2-[2,8-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0459]3-(4-[2-[2,8-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0460]3-(4-[2-[2,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0461]3-(4-[2-[2,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0462]3-(4-[2-[2,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0463]3-(4-[2-[2,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0464]3-(4-[2-[2,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0465]3-(4-[2-[2,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0466]3-(4-[2-[3,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0467]3-(4-[2-[3,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0468]3-(4-[2-[3,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0469]3-(4-[2-[3,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0470] 3-(4-[2-[3,7-Dibenzyl-5H-dibenzo[ad]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionic acid ethylester,

[0471]3-(4-[2-[3,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0472]2-Methoxy-3-(4-[2-[7-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0473]2-Methoxy-3-(4-[2-[7-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0474]2-Methoxy-3-(4-[2-[7-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0475]2-Methoxy-3-(4-[2-[7-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0476]2-Methoxy-3-(4-[2-[7-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0477]2-Methoxy-3-(4-[2-[7-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0478]2-Methoxy-3-(4-[2-[7-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0479]2-Methoxy-3-(4-[2-[7-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0480]2-Methoxy-3-(4-[2-[7-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0481]2-Methoxy-3-(4-[2-[7-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0482]2-Methoxy-3-(4-[2-[7-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0483]2-Methoxy-3-(4-[2-[7-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0484]2-Methoxy-3-(4-[2-[7-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0485]2-Methoxy-3-(4-[2-[7-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0486]2-Methoxy-3-(4-[2-[7-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0487]2-Methoxy-3-(4-[2-[7-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0488]2-Methoxy-3-(4-[2-[7-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0489]2-Methoxy-3-(4-[2-[7-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0490]2-Methoxy-3-(4-[2-[7-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0491]2-Methoxy-3-(4-[2-[7-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0492]2-Methoxy-3-(4-[2-[7-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0493]2-Methoxy-3-(4-[2-[7-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0494]2-Methoxy-3-(4-[2-[7-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0495]2-Methoxy-3-(4-[2-[7-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0496]2-Methoxy-3-(4-[2-[7-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0497]2-Methoxy-3-(4-[2-[7-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0498]2-Methoxy-3-(4-[2-[7-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0499]2-Methoxy-3-(4-[2-[7-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0500]2-Methoxy-3-(4-[2-[7-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0501]2-Methoxy-3-(4-[2-[7-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0502]2-Methoxy-3-(4-[2-[8-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0503]2-Methoxy-3-(4-[2-[8-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0504]2-Methoxy-3-(4-[2-[8-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0505]2-Methoxy-3-(4-[2-[8-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0506]2-Methoxy-3-(4-[2-[8-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0507]2-Methoxy-3-(4-[2-[8-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0508]2-Methoxy-3-(4-[2-[8-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0509]2-Methoxy-3-(4-[2-[8-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0510]2-Methoxy-3-(4-[2-[8-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0511]2-Methoxy-3-(4-[2-[8-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0512]2-Methoxy-3-(4-[2-[8-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0513]2-Methoxy-3-(4-[2-[8-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0514]2-Methoxy-3-(4-[2-[8-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0515]2-Methoxy-3-(4-[2-[8-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0516]2-Methoxy-3-(4-[2-[8-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0517]2-Methoxy-3-(4-[2-[8-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0518]2-Methoxy-3-(4-[2-[8-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0519]2-Methoxy-3-(4-[2-[8-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0520]2-Methoxy-3-(4-[2-[8-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0521]2-Methoxy-3-(4-[2-[8-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0522]2-Methoxy-3-(4-[2-[8-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0523]2-Methoxy-3-(4-[2-[8-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0524]2-Methoxy-3-(4-[2-[8-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0525]2-Methoxy-3-(4-[2-[8-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0526]2-Methoxy-3-(4-[2-[8-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0527]2-Methoxy-3-(4-[2-[8-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0528]2-Methoxy-3-(4-[2-[8-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0529]2-Methoxy-3-(4-[2-[8-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0530]2-Methoxy-3-(4-[2-[8-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0531]2-Methoxy-3-(4-[2-[8-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0532]2-Methoxy-3-(4-[2-[2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)ethoxy]-phenyl)-propionicacid,

[0533]2-Methoxy-3-(4-[2-[2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0534]2-Methoxy-3-(4-[2-[2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0535]2-Methoxy-3-(4-[2-[2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0536]2-Methoxy-3-(4-[2-[2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0537]2-Methoxy-3-(4-[2-[2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0538]2-Methoxy-3-(4-[2-[3-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0539]2-Methoxy-3-(4-[2-[3-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0540]2-Methoxy-3-(4-[2-[3-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0541]2-Methoxy-3-(4-[2-[3-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0542]2-Methoxy-3-(4-[2-[3-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0543]2-Methoxy-3-(4-[2-[3-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0544]3-(4-[2-[2,8-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0545]3-(4-[2-[2,8-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0546]3-(4-[2-[2,8-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0547]3-(4-[2-[2,8-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0548]3-(4-[2-[2,8-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0549]3-(4-[2-[2,8-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0550]3-(4-[2-[2,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0551]3-(4-[2-[2,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0552]3-(4-[2-[2,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0553]3-(4-[2-[2,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0554]3-(4-[2-[2,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0555]3-(4-[2-[2,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0556]3-(4-[2-[3,7-Dimethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0557]3-(4-[2-[3,7-Diethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0558]3-(4-[2-[3,7-Dipropyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0559]3-(4-[2-[3,7-Diphenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0560]3-(4-[2-[3,7-Dibenzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0561]3-(4-[2-[3,7-Diphenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0562]2-Methoxy-3-(4-[2-[7-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0563]2-Methoxy-3-(4-[2-[7-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0564]2-Methoxy-3-(4-[2-[7-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0565]2-Methoxy-3-(4-[2-[7-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0566]2-Methoxy-3-(4-[2-[7-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0567]2-Methoxy-3-(4-[2-[7-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0568]2-Methoxy-3-(4-[2-[7-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0569]2-Methoxy-3-(4-[2-[7-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0570]2-Methoxy-3-(4-[2-[7-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0571]2-Methoxy-3-(4-[2-[7-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0572]2-Methoxy-3-(4-[2-[7-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0573]2-Methoxy-3-(4-[2-[7-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0574]2-Methoxy-3-(4-[2-[7-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0575]2-Methoxy-3-(4-[2-[7-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0576]2-Methoxy-3-(4-[2-[7-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0577]2-Methoxy-3-(4-[2-[7-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0578]2-Methoxy-3-(4-[2-[7-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0579]2-Methoxy-3-(4-[2-[7-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0580]2-Methoxy-3-(4-[2-[7-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0581]2-Methoxy-3-(4-[2-[7-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0582]2-Methoxy-3-(4-[2-[7-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0583]2-Methoxy-3-(4-[2-[7-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0584]2-Methoxy-3-(4-[2-[7-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0585]2-Methoxy-3-(4-[2-[7-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0586]2-Methoxy-3-(4-[2-[7-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0587]2-Methoxy-3-(4-[2-[7-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0588]2-Methoxy-3-(4-[2-[7-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0589]2-Methoxy-3-(4-[2-[7-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0590]2-Methoxy-3-(4-[2-[7-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0591]2-Methoxy-3-(4-[2-[7-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0592]2-Methoxy-3-(4-[2-[8-ethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0593]2-Methoxy-3-(4-[2-[8-propyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0594]2-Methoxy-3-(4-[2-[8-phenyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0595]2-Methoxy-3-(4-[2-[8-benzyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0596]2-Methoxy-3-(4-[2-[8-phenylethyl-2-methyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0597]2-Methoxy-3-(4-[2-[8-methyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0598]2-Methoxy-3-(4-[2-[8-propyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0599]2-Methoxy-3-(4-[2-[8-phenyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0600]2-Methoxy-3-(4-[2-[8-benzyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0601]2-Methoxy-3-(4-[2-[8-phenylethyl-2-ethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0602]2-Methoxy-3-(4-[2-[8-methyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0603]2-Methoxy-3-(4-[2-[8-ethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0604]2-Methoxy-3-(4-[2-[8-phenyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0605]2-Methoxy-3-(4-[2-[8-benzyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0606]2-Methoxy-3-(4-[2-[8-phenylethyl-2-propyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0607]2-Methoxy-3-(4-[2-[8-methyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0608]2-Methoxy-3-(4-[2-[8-ethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0609]2-Methoxy-3-(4-[2-[8-propyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0610]2-Methoxy-3-(4-[2-[8-butyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0611]2-Methoxy-3-(4-[2-[8-phenylethyl-2-phenyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0612]2-Methoxy-3-(4-[2-[8-methyl-2-benxyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0613]2-Methoxy-3-(4-[2-[8-ethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0614]2-Methoxy-3-(4-[2-[8-propyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0615]2-Methoxy-3-(4-[2-[8-butyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0616]2-Methoxy-3-(4-[2-[8-phenylethyl-2-benzyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0617]2-Methoxy-3-(4-[2-[8-methyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0618]2-Methoxy-3-(4-[2-[8-ethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0619]2-Methoxy-3-(4-[2-[8-propyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0620]2-Methoxy-3-(4-[2-[8-butyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0621]2-Methoxy-3-(4-[2-[8-phenylethyl-2-phenylethyl-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-propionicacid,

[0622]2-Methoxy-3-(4-[2-[methyl-(2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0623]2-Methoxy-3-(4-[2-[methyl-(2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0624]2-Methoxy-3-(4-[2-[methyl-(2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0625]2-Methoxy-3-(4-[2-[methyl-(2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0626]2-Methoxy-3-(4-[2-[methyl-(2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0627]2-Methoxy-3-(4-[2-[methyl-(2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0628]2-Methoxy-3-(4-[2-[methyl-(3-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0629]2-Methoxy-3-(4-[2-[methyl-(3-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0630]2-Methoxy-3-(4-[2-[methyl-(3-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0631]2-Methoxy-3-(4-[2-[methyl-(3-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0632]2-Methoxy-3-(4-[2-[methyl-(3-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0633]2-Methoxy-3-(4-[2-[methyl-(3-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0634]3-(4-[2-[2,8-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0635]3-(4-[2-[2,8-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0636]3-(4-[2-[2,8-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0637]3-(4-[2-[2,8-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0638]3-(4-[2-[2,8-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0639]3-(4-[2-[2,8-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0640]3-(4-[2-[2,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0641]3-(4-[2-[2,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0642]3-(4-[2-[2,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0643]3-(4-[2-[2,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0644]3-(4-[2-[2,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0645]3-(4-[2-[2,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0646]3-(4-[2-[3,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0647]3-(4-[2-[3,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0648]3-(4-[2-[3,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0649]3-(4-[2-[3,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0650]3-4-[2-[3,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0651]3-(4-[2-[3,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid ethyl ester,

[0652]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0653]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0654]2-Methoxy-3-(4-[2-[methyl-(7-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0655]2-Methoxy-3-(4-[2-[methyl-(7-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0656]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0657]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0658]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0659]2-Methoxy-3-(4-[2-[methyl-(7-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0660]2-Methoxy-3-(4-[2-[methyl-(7-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0661]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0662]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0663]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0664]2-Methoxy-3-(4-[2-[methyl-(7-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0665]2-Methoxy-3-(4-[2-[methyl-(7-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0666]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0667]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0668]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0669]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0670]2-Methoxy-3-(4-[2-[methyl-(7-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0671]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0672]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0673]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0674]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0675]2-Methoxy-3-(4-[2-[methyl-(7-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0676]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0677]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0678]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0679]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0680]2-Methoxy-3-(4-[2-[methyl-(7-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0681]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0682]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0683]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0684]2-Methoxy-3-(4-[2-[methyl-(8-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0685]2-Methoxy-3-(4-[2-[methyl-(8-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0686]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0687]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0688]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0689]2-Methoxy-3-(4-[2-[methyl-(8-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0690]2-Methoxy-3-(4-[2-[methyl-(8-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0691]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0692]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0693]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0694]2-Methoxy-3-(4-[2-[methyl-(8-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0695]2-Methoxy-3-(4-[2-[methyl-(8-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0696]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]ethoxy]-phenyl)-propionicacid ethyl ester,

[0697]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0698]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0699]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0700]2-Methoxy-3-(4-[2-[methyl-(8-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0701]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0702]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0703]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0704]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0705]2-Methoxy-3-(4-[2-[methyl-(8-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0706]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0707]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0708]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0709]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0710]2-Methoxy-3-(4-[2-[methyl-(8-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0711]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid ethyl ester,

[0712]2-Methoxy-3-(4-[2-[methyl-(2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0713]2-Methoxy-3-(4-[2-[methyl-(2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0714]2-Methoxy-3-(4-[2-[methyl-(2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0715]2-Methoxy-3-(4-[2-[methyl-(2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0716]2-Methoxy-3-(4-[2-[methyl-(2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0717]2-Methoxy-3-(4-[2-[methyl-(2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0718]2-Methoxy-3-(4-[2-[methyl-(3-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]-ethoxy]-phenyl)-propionicacid,

[0719]2-Methoxy-3-(4-[2-[methyl-(3-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0720]2-Methoxy-3-(4-[2-[methyl-(3-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0721]2-Methoxy-3-(4-[2-[methyl-(3-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0722]2-Methoxy-3-(4-[2-[methyl-(3-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0723]2-Methoxy-3-(4-[2-[methyl-(3-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0724]3-(4-[2-[2,8-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0725]3-(4-[2-[2,8-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0726]3-(4-[2-[2,8-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0727]3-(4-[2-[2,8-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0728]3-(4-[2-[2,8-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0729]3-(4-[2-[2,8-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0730]3-(4-[2-[2,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0731]3-(4-[2-[2,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0732]3-(4-[2-[2,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0733]3-(4-[2-[2,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0734]3-(4-[2-[2,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0735]3-(4-[2-[2,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0736]3-(4-[2-[3,7-Dimethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0737]3-(4-[2-[3,7-Diethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0738]3-(4-[2-[3,7-Dipropyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0739]3-(4-[2-[3,7-Diphenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0740]3-(4-[2-[3,7-Dibenzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0741]3-(4-[2-[3,7-Diphenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy]-phenyl)-2-methoxy-propionicacid,

[0742]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0743]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0744]2-Methoxy-3-(4-[2-[methyl-(7-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0745]2-Methoxy-3-(4-[2-[methyl-(7-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0746]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0747]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0748]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0749]2-Methoxy-3-(4-[2-[methyl-(7-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0750]2-Methoxy-3-(4-[2-[methyl-(7-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0751]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0752]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0753]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0754]2-Methoxy-3-(4-[2-[methyl-(7-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0755]2-Methoxy-3-(4-[2-[methyl-(7-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0756]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0757]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0758]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0759]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0760]2-Methoxy-3-(4-[2-[methyl-(7-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0761]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0762]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0763]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0764]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0765]2-Methoxy-3-(4-[2-[methyl-(7-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0766]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0767]2-Methoxy-3-(4-[2-[methyl-(7-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0768]2-Methoxy-3-(4-[2-[methyl-(7-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0769]2-Methoxy-3-(4-[2-[methyl-(7-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0770]2-Methoxy-3-(4-[2-[methyl-(7-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0771]2-Methoxy-3-(4-[2-[methyl-(7-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0772]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0773]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0774]2-Methoxy-3-(4-[2-[methyl-(8-phenyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0775]2-Methoxy-3-(4-[2-[methyl-(8-benzyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0776]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0777]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0778]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0779]2-Methoxy-3-(4-[2-[methyl-(8-phenyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0780]2-Methoxy-3-(4-[2-[methyl-(8-benzyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0781]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0782]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0783]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0784]2-Methoxy-3-(4-[2-[methyl-(8-phenyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0785]2-Methoxy-3-(4-[2-[methyl-(8-benzyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0786]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-propyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0787]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0788]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0789]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0790]2-Methoxy-3-(4-[2-[methyl-(8-butyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0791]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0792]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-benxyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0793]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0794]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0795]2-Methoxy-3-(4-[2-[methyl-(8-butyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0796]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-benzyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0797]2-Methoxy-3-(4-[2-[methyl-(8-methyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0798]2-Methoxy-3-(4-[2-[methyl-(8-ethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0799]2-Methoxy-3-(4-[2-[methyl-(8-propyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino)-ethoxy]-phenyl)-propionicacid,

[0800]2-Methoxy-3-(4-[2-[methyl-(8-butyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0801]2-Methoxy-3-(4-[2-[methyl-(8-phenylethyl-2-phenylethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amino]-ethoxy]-phenyl)-propionicacid,

[0802]3-(4-[2-[5H-Dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0803]3-(4-[2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0804]3-(4-[2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0805]3-(4-[2-(6,11-Dihydrodibenzo[b,e]oxepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0806]3-(4-[2-(2,10-Dichloro-12H-5,7-dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester,

[0807]3-(4-[2-(2,10-Dichloro-12H-5,7-dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid,

[0808]2-Ethoxy-3-(4-[2-(2-methyl-9,10-dihydro-4H-1-oxa-3-aza-benzo[f]azulen-4-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester,

[0809]3-(4-[2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propanoicacid ethyl ester,

[0810]3-(4-[2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propanoicacid,

[0811]3-(4-[2-([10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino)-ethoxy]-phenyl)-2-ethoxypropanoicacid ethyl ester,

[0812]3-(4-[2-([10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl]-methyl-amino)-ethoxy]-phenyl)-2-ethoxypropanoicacid,

[0813]3-{4-[2-(6,11-Dihydro-dibenzo[b,e]oxepin-11-ylsulfanyl)-ethoxy]-phenyl}-2-ethoxy-propionicacid,

[0814]2-Ethoxy-3-{4-[2-(5-methyl-6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yloxy)-ethoxy]-phenyl}-propionicacid,

[0815]3-{4-[2-(4,9-Dihydro-1,10-dithia-benzo[f]azulen-4-yloxy)-ethoxy]-phenyl}-2-ethoxy-propionicacid, or

[0816]3-{4-[2-(12H-5,7-Dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl}-2-ethoxy-propionicacid;

[0817] or a pharmaceutically acceptable salt thereof.

[0818] Further preferred compounds of the invention are:

[0819]3-{4-[2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl}-2-ethoxy-propionicacid,

[0820]3-{4-[2-(6,11-Dihydro-dibenzo[b,e]oxepin-11-ylsulfanyl)-ethoxy]-phenyl}-2-ethoxy-propionicacid,

[0821]3-(4-{2-[(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-methyl-amino]-ethoxy}-phenyl)-2-ethoxy-propionicacid,

[0822]2-Ethoxy-3-{4-[2-(5-methyl-6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yloxy)-ethoxy]-phenyl}-propionicacid,

[0823]3-{4-[2-(4,9-Dihydro-1,10-dithia-benzo[f]azulen-4-yloxy)-ethoxy]-phenyl}-2-ethoxy-propionicacid, and

[0824]3-{4-[2-(12H-5,7-Dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl}-2-ethoxy-propionicacid;

[0825] or a pharmaceutically acceptable salt thereof.

[0826] In the above structural formulas and throughout the presentspecification, the following terms have the indicated meaning:

[0827] The term “C₁₋₁₂-alkyl” as used herein, in alone or incombination, refers to a straight or branched, saturated hydrocarbonchain having the indicated number of carbon atoms such as, e.g., methyl,ethyl, n-propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl,pentyl, isopentyl, hexyl, isohexyl and the like.

[0828] The term “C₃₋₈-cycloalkyl” as used herein refers to a radical ofa saturated cyclic hydrocarbon with the indicated number of carbon atomssuch as, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl or cyclooctyl.

[0829] The terms “C_(2-n′)-alkenyl” wherein n′ can be from 3 through 15,as used herein, represents an olefinically unsaturated branched orstraight group having from 2 to the specified number of carbon atoms andat least one double bond. Examples of such groups include, but are notlimited to, vinyl, 1-propenyl, 2-propenyl, allyl, iso-proppenyl,1,3-butadienyl, 1-butenyl, hexenyl, pentenyl, and the like.

[0830] The terms “C_(2-n′)-alkynyl” wherein n′ can be from 3 through 15,as used herein, represent an unsaturated branched or straight grouphaving from 2 to the specified number of carbon atoms and at least onetriple bond. Examples of such groups include, but are not limited to,1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl andthe like.

[0831] The terms “C_(4-n′)-alkenynyl” wherein n′ can be from 5 through15, as used herein, represent an unsaturated branched or straighthydrocarbon group having from 4 to the specified number of carbon atomsand both at least one double bond and at least one triple bond. Examplesof such groups include, but are not limited to, 1-penten-4-yne,3-penten-1-yne, 1,3-hexadiene-5-yne and the like.

[0832] The term “C₁₋₁₂-alkoxy” as used herein, alone or in combinationis intended to include those C₁₋₁₂-alkyl groups of the designated lengthin either a linear or branched or cyclic configuration linked thorugh anether oxygen having its free valence bond from the ether oxygen.Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy,pentoxy and hexoxy. Examples of branched alkoxy are isoprpoxy,sec-butoxy, tert-butoxy, isopentoxy and isohexoxy. Example of cyclicalkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy andcyclohexyloxy.

[0833] The term “C₁₋₆alkoxycarbonyloxy” is intended to include the abovedefined C₁₋₆alkoxy groups attached to a carbonyloxy moiety, eg.methoxycarbonyloxy, ethoxycarbonyloxy, etc.

[0834] As used herein the term “C₄₋₁₂-(cycloalkylalkyl)” represents abranched or straight alkyl group substituted at a carbon with acycloalkyl group. Examples of such groups include, but are not limitedto, cyclopropylethyl, cyclobutylmethyl, 2-(cyclohexyl)ethyl,cyclohexylmethyl, 3-(cyclopentyl)-1-propyl, and the like.

[0835] The term “C₁₋₁₂-alkylthio” as used herein, alone or incombination, refers to a straight or branched or cyclic monovalentsubstituent comprising a C₁₋₁₂-alkyl group linked through a divalentsulfur atom having its free valence bond from the sulfur atom and having1 to 12 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio,pentylthio. Example of cyclic alkylthio are cyclopropylthio,cyclobutylthio, cyclopentylthio and cyclohexylthio.

[0836] The term “C₁₋₁₂alkylamino” as used herein, alone or incombination, refers to a straight or branched or cyclic monovalentsubstituent comprising a C₁₋₁₂-alkyl group linked through amino having afree valence bond from the nitrogen atom e.g. methylamino, ethylamino,propylamino, butylamino, pentylamino. Example of cyclic alkylamino arecyclopropylamino, cyclobutylamino, cyclopentylamino and cyclohexylamino.

[0837] The term “hydroxyC₁₋₁₂alkyl” as used herein, alone or incombination, refers to a C₁₋₁₂alkyl as defined herein whereto isattached a hydroxy group, e.g. hydroxyethyl, 1-hydroxypropyl,2-hydroxypropyl etc.

[0838] The term “arylamino” as used herein, alone or in combination,refers to an aryl as defined herein linked through amino having a freevalence bond from the nitrogen atom e.g. phenylamino, naphthylamino,etc.

[0839] The term “aralkylamino” as used herein, alone or in combination,refers to an aralkyl as defined herein linked through amino having afree valence bond from the nitrogen atom e.g. benzylamino,phenethylamino, 3-phenylpropylamino, 1-naphtylmethylamino,2-(1-naphtyl)ethylamino and the like.

[0840] The term “aminoC₁₋₁₂alkyl” as used herein, alone or incombination, refers to a C₁₋₁₂alkyl as defined herein whereto isattached an amino group, e.g. aminoethyl, 1-aminopropyl, 2-aminopropyletc.

[0841] The term “aryloxycarbonyl” as used herein, alone or incombination, refers to an aryloxy as defined herein linked through acarbonyl having a free valence bond from the carbon atom, e.g.phenoxycarbonyl, 1-naphthyloxycarbonyl or 2-naphthyloxycarbonyl, etc.

[0842] The term “aralkoxycarbonyl” as used herein, alone or incombination, refers to an aralkoxy as defined herein linked through acarbonyl having a free valence bond from the carbon atom, e.g.benzyloxycarbonyl, phenethoxycarbonyl, 3-phenylpropoxycarbonyl,1-naphthylmethoxycarbonyl, 2-(1-naphtyl)ethoxycarbonyl, etc.

[0843] The term “C₁₋₁₂alkoxyC₁₋₁₂alkyl” as used herein, alone or incombination, refers to a C₁₋₁₂alkyl as defined herein whereto isattached a C₁₋₁₂alkoxy as defined herein, e.g. methoxymethyl,ethoxymethyl, methoxyethyl, ethoxyethyl, etc.

[0844] The term “aryloxyC₁₋₁₂alkyl” as used herein, alone or incombination, refers to a C₁₋₁₂alkyl as defined herein whereto isattached an aryloxy as defined herein, e.g. phenoxymethyl,phenoxydodecyl, 1-naphthyloxyethyl, 2-naphthyloxypropyl, etc.

[0845] The term “aralkoxyC₁₋₁₂alkyl” as used herein, alone or incombination, refers to a C₁₋₁₂alkyl as defined herein whereto isattached an aralkoxy as defined herein, e.g. benzyloxymethyl,phenethoxydodecyl, 3-phenylpropoxyethyl, 1-naphthylmethoxypropyl,2-(1-naphtyl)ethoxymethyl, etc.

[0846] The term “thioC₁₋₁₂alkyl” as used herein, alone or incombination, refers to a C₁₋₁₂alkyl as defined herein whereto isattached a group of formula —SR′″ wherein R′″ is hydrogen, C₁₋₆alkyl oraryl, e.g. thiomethyl, methylthiomethyl, phenylthioethyl, etc.

[0847] The term “C₁₋₁₂alkoxycarbonylamino” as used herein, alone or incombination, refers to a C₁₋₁₂alkoxycarbonyl as defined herein linkedthrough amino having a free valence bond from the nitrogen atom e.g.methoxycarbonylamino, carbethoxyamino, propoxycarbonylamino,isopropoxycarbonylamino, n-butoxycarbonylamino,tert-butoxycarbonylamino, etc.

[0848] The term “aryloxycarbonylamino” as used herein, alone or incombination, refers to an aryloxycarbonyl as defined herein linkedthrough amino having a free valence bond from the nitrogen atom e.g.phenoxycarbonylamino, 1-naphthyloxycarbonylamino or2-naphthyloxycarbonylamino, etc.

[0849] The term “aralkoxycarbonylamino” as used herein, alone or incombination, refers to an aralkoxycarbonyl as defined herein linkedthrough amino having a free valence bond from the nitrogen atom e.g.benzyloxycarbonylamino, phenethoxycarbonylamino,3-phenylpropoxycarbonylamino, 1-naphthylmethoxycarbonylamino,2-(1-naphtyl)ethoxycarbonylamino, etc.

[0850] The term “aryl” is intended to include aromatic rings, such ascarboxylic aromatic rings selected from the group consisting of phenyl,naphthyl, (1-naphtyl or 2-naphtyl) optionally substituted with halogen,amino, hydroxy, C₁₋₆alkyl or C₁₋₆-alkoxy.

[0851] The term “arylene” is intended to include divalent aromaticrings, such as carboxylic aromatic rings selected from the groupconsisting of phenylene, naphthylene, optionally substituted withhalogen, amino, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy.

[0852] The term “halogen” means fluorine, chlorine, bromine or iodine.

[0853] The term “perhalomethyl” means trifluoromethyl, trichloromethyl,tribromomethyl or triiodomethyl.

[0854] The term “C₁₋₆-dialkylamino” as used herein refers to an aminogroup wherein the two hydrogen atoms independently are substituted witha straight or branched, saturated hydrocarbon chain having the indicatednumber of carbon atoms; such as dimethylamino, N-ethyl-N-methylamino,diethylamino, dipropylamino, N-(n-butyl)-N-methylamino,di(n-pentyl)amino, and the like.

[0855] The term “acyl” as used herein refers to a monovalent substituentcomprising a C₁₋₆alkyl group linked through a carbonyl group; such ase.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl, and thelike.

[0856] The term “acyloxy” as used herein refers to acyl as definedherein linked to an oxygen atom having its free valence bond from theoxygen atom e.g. acetyloxy, propionyloxy, butyryloxy, isobutyryloxy,pivaloyloxy, valeryloxy, and the like.

[0857] The term “C₁₋₁₂-alkoxycarbonyl” as used herein refers to amonovalent substituent comprising a C₁₋₁₂-alkoxy group linked through acarbonyl group; such as e.g. methoxycarbonyl, carbethoxy,propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl,sec-butoxycarbonyl, tert-butoxycarbonyl, 3-methylbutoxycarbonyl,n-hexoxycarbonyl and the like.

[0858] The term “a cyclic ring containing from 5 to 7 carbon atoms” asused herein refers to a monocyclic saturated or unsaturated or aromaticsystem, wherein the ring may be cyclopentyl, cyclopentenyl, cyclohexyl,phenyl or cycloheptyl.

[0859] The term “bicycloalkyl” as used herein refers to a monovalentsubstituent comprising a bicyclic structure made of 6-12 carbon atomssuch as e.g. 2-norbornyl, 7-norbornyl, 2-bicyclo[2.2.2]octyl and9-bicyclo[3.3.1]nonanyl.

[0860] The term “heteroaryl” as used herein, alone or in combination,refers to a monovalent substituent comprising a 5-6 membered monocyclicaromatic system or a 9-10 membered bicyclic aromatic system containingone or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g.furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine,pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole,oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline,quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine.

[0861] The term “heteroarylene” as used herein, alone or in combination,refers to a divalent group comprising a 5-6 membered monocyclic aromaticsystem or a 9-10 membered bicyclic aromatic system containing one ormore heteroatoms selected from nitrogen, oxygen and sulfur, e.g. furan,thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine,pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole,thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole,benzimidazole, benzofuran, pteridine and purine.

[0862] The term “heteroaryloxy” as used herein, alone or in combination,refers to a heteroaryl as defined herein linked to an oxygen atom havingits free valence bond from the oxygen atom e.g. pyrrole, imidazole,pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine,isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline,isoquinoline, quinazoline, quinoxaline, indole, benzimidazole,benzofuran, pteridine and purine linked to oxygen.

[0863] The term “aralkyl” as used herein refers to a straight orbranched saturated carbon chain containing from 1 to 6 carbonssubstituted with an aromatic carbohydride; such as benzyl, phenethyl,3-phenylpropyl, 1-naphtylmethyl, 2-(1-naphtyl)ethyl and the like.

[0864] The term “aryloxy” as used herein refers to phenoxy,1-naphthyloxy or 2-naphthyloxy.

[0865] The term “aralkoxy” as used herein refers to a C₁₋₆-alkoxy groupsubstituted with an aromatic carbohydride, such as benzyloxy,phenethoxy, 3-phenylpropoxy, 1-naphthylmethoxy, 2-(1-naphtyl)ethoxy andthe like.

[0866] The term “heteroaralkyl” as used herein refers to a straight orbranched saturated carbon chain containing from 1 to 6 carbonssubstituted with a heteroaryl group; such as (2-furyl)methyl,(3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl,(2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl and the like.

[0867] The term “heteroaralkoxy” as used herein refers to aheteroaralkyl as defined herein linked to an oxygen atom having its freevalence bond from the oxygen atom, e.g. (2-furyl)methyl,(3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl,(2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl linked to oxygen.

[0868] The term “C₁₋₆-alkylsulfonyl” as used herein refers to amonovalent substituent comprising a C₁₋₆alkyl group linked through asulfonyl group such as e.g. methylsulfonyl, ethylsulfonyl,n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl,isobutylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl,2-methylbutylsulfonyl, 3-methylbutylsulfonyl, n-hexylsulfonyl,4-methylpentylsulfonyl, neopentylsulfonyl, n-hexylsulfonyl and2,2-dimethylpropylsulfonyl.

[0869] The term “C₁₋₆-monoalkylaminosulfonyl” as used herein refers to amonovalent substituent comprising a C₁₋₆-monoalkylamino group linkedthrough a sulfonyl group such as e.g. methylaminosulfonyl,ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl,n-butylaminosulfonyl, sec-butylaminosulfonyl, isobutylaminosulfonyl,tert-butylaminosulfonyl, n-pentylaminosulfonyl,2-methylbutylaminosulfonyl, 3-methylbutylaminosulfonyl,n-hexylaminosulfonyl, 4-methylpentylaminosulfonyl,neopentylaminosulfonyl, n-hexylaminosulfonyl and2,2-dimethylpropylaminosulfonyl.

[0870] The term “C₁₋₆-dialkylaminosulfonyl” as used herein refers to amonovalent substituent comprising a C₁₋₆-dialkylamino group linkedthrough a sulfonyl group such as dimethylaminosulfonyl,N-ethyl-N-methylaminosulfonyl, diethylaminosulfonyl,dipropylaminosulfonyl, N-(n-butyl)-N-methylaminosulfonyl,di(n-pentyl)aminosulfonyl, and the like.

[0871] The term “C₁₋₆-alkylsulfinyl” as used herein refers to amonovalent substituent comprising a straight or branched C₁₋₆-alkylgroup linked through a sulfinyl group (—S(═O)—); such as e.g.methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl,pentylsulfinyl, and the like.

[0872] The term “acylamino” as used herein refers to an amino groupwherein one of the hydrogen atoms is substituted with an acyl group,such as e.g. acetamido, propionamido, isopropylcarbonylamino, and thelike.

[0873] The term “(C₃₋₆-cycloalkyl)C₁₋₆-alkyl” as used herein, alone orin combination, refers to a straight or branched, saturated hydrocarbonchain having 1 to 6 carbon atoms and being monosubstituted with aC₃₋₆-Cycloalkyl group, the cycloalkyl group optionally being mono- orpolysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; suchas e.g. cyclopropylmethyl, (1-methylcyclopropyl)methyl,1-(cyclopropyl)ethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

[0874] The term “arylthio” as used herein, alone or in combination,refers to an aryl group linked through a divalent sulfur atom having itsfree valence bond from the sulfur atom, the aryl group optionally beingmono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy orC₁₋₆-alkoxy; e.g. phenylthio, (4-methylphenyl)-thio,(2-chlorophenyl)thio, and the like.

[0875] The term “arylsulfinyl” as used herein refers to an aryl grouplinked through a sulfinyl group (—S(═O)—), the aryl group optionallybeing mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy orC₁₋₆-alkoxy; such as e.g. phenylsulfinyl, (4-chlorophenyl)sulfinyl, andthe like.

[0876] The term “arylsulfonyl” as used herein refers to an aryl grouplinked through a sulfonyl group, the aryl group optionally being mono-or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy;such as e.g. phenylsulfonyl, tosyl, and the like.

[0877] The term “C₁₋₆-monoalkylaminocarbonyl” as used herein refers to amonovalent substituent comprising a C₁₋₆-monoalkylamino group linkedthrough a carbonyl group such as e.g. methylaminocarbonyl,ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl,n-butylaminocarbonyl, sec-butylaminocarbonyl, isobutylaminocarbonyl,tert-butylaminocarbonyl, n-pentylaminocarbonyl,2-methylbutylaminocarbonyl, 3-methylbutylaminocarbonyl,n-hexylaminocarbonyl, 4-methylpentylaminocarbonyl,neopentylaminocarbonyl, n-hexylaminocarbonyl and2-2-dimethylpropylaminocarbonyl.

[0878] The term “C₁₋₆-dialkylaminocarbonyl” as used herein refers to amonovalent substituent comprising a C₁₋₆-dialkylamino group linkedthrough a carbonyl group such as dimethylaminocarbonyl,N-ethyl-N-methylaminocarbonyl, diethylaminocarbonyl,dipropylaminocarbonyl, N-(n-butyl)-N-methylaminocarbonyl,di(n-pentyl)aminocarbonyl, and the like.

[0879] The term “C₁₋₆-monoalkylaminocarbonylamino” as used herein refersto an amino group wherein one of the hydrogen atoms is substituted witha C₁₋₆-monoalkylaminocarbonyl group, e.g. methylaminocarbonylamino,ethylamino-arbonylamino, n-propylaminocarbonylamino,iso-propylaminocarbonylamino, n-butylaminocarbonylamino,sec-butylaminocarbonylamino, isobutylaminocarbonylamino,tert-butylaminocarbonylamino, and 2-methylbutylaminocarbonylamino.

[0880] The term “C₁₋₆-dialkylaminocarbonylamino” as used herein refersto an amino group wherein one of the hydrogen atoms is substituted witha C₁₋₆-dialkylaminocarbonyl group, such as di-methylaminocarbonylamino,N-ethyl-N-methylaminocarbonylamino, diethylaminocarbonylamino,dipropylaminocarbonylamino, N-(n-butyl)-N-methylaminocarbonylamino,di(n-pentyl)aminocarbonylamino, and the like.

[0881] As used herein, the phrase “heterocyclyl” means a monovalentsaturated or unsaturated group being monocyclic and containing one ormore, such as from one to four carbon atom(s), and from one to four N, Oor S atom(s) or a combination thereof. The phrase “heterocyclyl”includes, but is not limited to, 5-membered heterocycles having onehetero atom (e.g. pyrrolidine, pyrroline); 5-membered heterocycleshaving two heteroatoms in 1, 2 or 1,3 positions (e.g. pyrazoline,pyrazolidine, 1,2-oxathiolane, imidazolidine, imidazoline, 4-oxazolone);5-membered heterocycles having three heteroatoms (e.g.tetrahydrofurazan); 5-membered heterocycles having four heteroatoms;6-membered heterocycles with one heteroatom (e.g. piperidine);6-membered heterocycles with two heteroatoms (e.g. piperazine,morpholine); 6-membered heterocycles with three heteroatoms; and6-membered heterocycles with four heteroatoms.

[0882] As used herein, the phrase “a divalent heterocyclic group” meansa divalent saturated or unsaturated system being monocyclic andcontaining one or more, such as from one to four carbon atom(s), and oneto four N, O or S atom(s) or a combination thereof. The phrase adivalent heterocyclic group includes, but is not limited to, 5-memberedheterocycles having one hetero atom (e.g. pyrrolidine, pyrroline);5-membered heterocycles having two heteroatoms in 1, 2 or 1,3 positions(e.g. pyrazoline, pyrazolidine, 1,2-oxathiolane, imidazolidine,imidazoline, 4-oxazolone); 5-membered heterocycles having threeheteroatoms (e.g. tetrahydrofurazan); 5-membered heterocycles havingfour heteroatoms; 6-membered heterocycles with one heteroatom (e.g.piperidine); 6-membered heterocycles with two heteroatoms (e.g.piperazine, morpholine); 6-membered heterocycles with three heteroatoms;and 6-membered heterocycles with four heteroatoms.

[0883] As used herein, the phrase “a 5-6 membered cyclic ring” means anunsaturated or saturated or aromatic system containing one or morecarbon atoms and optionally from one to four N, O or S atom(s) or acombination thereof. The phrase “a 5-6 membered cyclic ring” includes,but is not limited to, e.g. cyclopentyl, cyclohexyl, phenyl,cyclohexenyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl,pyrazolinyl, piperidyl, piperazinyl, pyrrolyl, 2H-pyrrolyl, imidazolyl,pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,morpholinyl, thiomorpholinyl, isothiazolyl, isoxazolyl, oxazolyl,oxadiazolyl, thiadiazolyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 5-memberedheterocycles having one hetero atom (e.g. thiophenes, pyrroles, furans);5-membered heterocycles having two heteroatoms in 1,2 or 1,3 positions(e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-memberedheterocycles having three heteroatoms (e.g. triazoles, thiadiazoles);5-membered heterocycles having four heteroatoms; 6-membered heterocycleswith one heteroatom (e.g. pyridine, quinoline, isoquinoline,phenanthridine, cyclohepta[b]pyridine); 6-membered heterocycles with twoheteroatoms (e.g. pyridazines, cinnolines, phthalazines, pyrazines,pyrimidines, quinazolines, morpholines); 6-membered heterocycles withthree heteroatoms (e.g. 1,3,5-triazine); and 6-membered heterocycleswith four heteroatoms.

[0884] As used herein, the phrase “5- or 6-membered nitrogen containingring” refers to a monovalent substituent comprising a monocyclicunsaturated or saturated or aromatic system containing one or morecarbon, nitrogen, oxygen or sulfur atoms or a combination thereof andhaving 5 or 6 members, e.g. pyrrolidinyl, pyrrolinyl, imidazolidinyl,pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, pyrrolyl,2H-pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl,pyrimidinyl, pyridazinyl, morpholinyl, thiomorpholinyl, isothiazolyl,isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, 1,3-dioxolanyl and1,4-dioxolanyl.

[0885] Certain of the above defined terms may occur more than once inthe above formula (Ia), and upon such occurence each term shall bedefined independently of the other.

[0886] Pharmaceutically acceptable salts forming part of this inventioninclude salts of the carboxylic acid moiety such as alkali metal saltslike Li, Na, and K salts, alkaline earth metal salts like Ca and Mgsalts, salts of organic bases such as lysine, arginine, guanidine,diethanolamine, choline and the like, ammonium or substituted ammoniumsalts, aluminum salts. Salts may include acid addition salts whereappropriate which are, sulphates, nitrates, phosphates, perchlorates,borates, hydrohalides, acetates, tartrates, maleates, citrates,succinates, palmoates, methanesulplionates, benzoates, salicylates,hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates,ketoglutarates and the like. Pharmaceutically acceptable solvates may behydrates or comprising other solvents of crystallization such asalcohols.

[0887] The pharmaceutically acceptable salts are prepared by reactingthe compound of formula (Ia) with 1 to 4 equivalents of a base such assodium hydroxide, sodium methoxide, sodium hydride, potassiumt-butoxide, calcium hydroxide, magnesium hydroxide and the like, insolvents like ether, THF, methanol, t-butanol, dioxane, isopropanol,ethanol etc. Mixture of solvents may be used. Organic bases like lysine,arginine, diethanolamine, choline, guandine and their derivatives etc.may also be used. Alternatively, acid addition salts wherever applicableare prepared by treatment with acids such as hydrochloric acid,hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid,p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid,maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid,palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid,tartaric acid and the like in solvents like ethyl acetate, ether,alcohols, acetone, THF, dioxane etc. Mixture of solvents may also beused.

[0888] The stereoisomers of the compounds forming part of this inventionmay be prepared by using reactants in their single enantiomeric form inthe process wherever possible or by conducting the reaction in thepresence of reagents or catalysts in their single enantiomer form or byresolving the mixture of stereoisomers by conventional methods. Some ofthe preferred methods include use of microbial resolution, resolving thediastereomeric salts formed with chiral acids such as mandelic acid,camphorsulfonic acid, tartaric acid, lactic acid, and the like whereverapplicable or chiral bases such as brucine, cinchona alkaloids and theirderivatives and the like. Commonly used methods are compiled by Jaqueset al in “Enantiomers, Racemates and Resolution” (Wiley Interscience,1981). More specifically the compound of formula (Ia) may be convertedto a 1:1 mixture of diastereomeric amides by treating with chiralamines, aminoacids, aminoalcohols derived from aminoacids; conventionalreaction conditions may be employed to convert acid into an amide; thedia-stereomers may be separated either by fractional crystallization orchromatography and the stereoisomers of compound of formula (Ia) may beprepared by hydrolysing the pure diastereomeric amide.

[0889] Various polymorphs of compounds of formula (Ia) forming part ofthis invention may be prepared by crystallization of compounds offormula (Ia) under different conditions. For example, using differentsolvents commonly used or their mixtures for recrystallization;crystallizations at different temperatures; various modes of cooling,ranging from very fast to very slow cooling during crystallizations.Polymorphs may also be obtained by heating or melting the compoundfollowed by gradual or fast cooling. The presence of polymorphs may bedetermined by solid probe NMR spectroscopy, IR spectroscopy,differential scanning calorimetry, powder X-ray diffraction or suchother techniques.

[0890] The invention also relate to methods of preparing the abovementioned compounds, comprising:

[0891] a) reacting a compound of formula II

[0892]  wherein R¹-R⁴, A, X and Q are defined as above, with a compoundof formula III

[0893]  wherein L is a leaving group such as halogen,p-toluenesulfonate, methanesulfonate and the like and wherein n, Z, Ar,R⁵-R⁸ are defined as above except that R⁸ is not H, to obtain a compoundof formula (Ia) wherein n, Z, Ar, R¹-R⁸, A, X and Q are defined as aboveexcept that R⁸ is not H.

[0894] b) reacting a compound of formula IV

[0895]  wherein R¹-R⁴, A, X, Q and n are defined as above, with acompound of formula V

[0896]  wherein Z, Ar and R⁵-R⁸ are defined as above except that R⁸ isnot H, by using suitable coupling agents such as dicyclohexyl urea,triarylphosphine/dialkylazadicarboxylate such as PPh₃/DEAD(Diethylazodicarboxylate) and the like, to obtain a compound of formula(Ia), wherein n, Ar, R¹-R⁸, A, X, Z and Q are defined as above exceptthat R⁸ is not H, and Z is not C.

[0897] c) reacting a compound of formula VI

[0898]  wherein L is a leaving group such as halogen,p-toluenesulfonate, methanesulfonate and the like and wherein R¹-R⁴, A,X, Q and n are defined as above, with an compound of formula V

[0899]  wherein Z, Ar and R⁵-R⁸ are defined as above except that R³ isnot H, to obtain a compound of formula (Ia) wherein n, Ar, R¹-R⁸, A, X,Z and Q are defined as above except that R⁸ is not H and Z is not C.

[0900] d) reacting a compound of formula VII

[0901]  wherein R¹-R⁴, A, X, 0, Z, Ar, and n are defined as above, withan compound of formula VIII

[0902]  wherein R⁶-R⁸ are defined as above except that R⁸ is not H, toobtain the β-hydroxy aldol product, which may be dehydroxylated ordehydrated to obtain a compound of formula (Ia) wherein n, Ar, R¹-R⁸, A,X, Z and Q are defined as above except that R⁸ is not H.

[0903] e) reacting a compound of formula VII

[0904]  wherein R¹-R⁴, A, X, Q, Z, Ar and n are defined as above, withan compound of formula IX

[0905]  wherein R⁷ and R⁸ are defined as above except that R⁸ is not H,and wherein R¹¹ is a lower alkyl group to obtain a compound of formula(Ia) wherein n, Ar, R¹-R⁴, R⁷-R⁸, A, X, Z and Q are defined as aboveexcept that R⁸ is not H and wherein R⁵ forms a bond together with R⁶.

[0906] f) hydrogenation of a compound of formula X

[0907]  wherein n, Ar, R¹-R⁴, R⁷-R⁸, A, X, Z and Q are defined as aboveexcept that R⁸ is not H, to obtain a compound of formula (Ia) wherein n,Ar, R¹-R⁴, R⁷-R⁸, A, X, Z and Q are defined as above except that R⁸ isnot H and wherein R⁵ and R⁶ is hydrogen.

[0908] g) reacting a compound of formula XI

[0909]  wherein L is a leaving group such as halogen and R¹-R⁸, A, X, Q,Z and n are defined as above except that R⁸ is not H, with an alcohol offormula XII

HO—R⁷  XII

[0910] wherein R⁷ is defined as above, to obtain a compound of formula(Ia) wherein n, Ar, R¹-R⁸, R⁷, A, X, Z and Q is defined as above exceptthat R⁸ is not H.

[0911] h) reacting a compound of formula XIII

[0912]  wherein n, Ar, R¹-R⁶, A, X, Z and Q is defined as above andwherein R⁸ is defined as above except that R⁸ is not H, with a compoundof formula XIV

Hal-R⁷  XIV

[0913] wherein R⁷ is defined as above and wherein “Hal” represents Cl,Br, or I to obtain a compound of formula (Ia) wherein n, Ar, R¹-R⁸, A,X, Z and Q is defined as above except that R is not H.

[0914] i) reacting a compound of formula VI

[0915]  wherein L is a leaving group such as halogen,p-toluenesulfonate, methanesulfonate and the like and wherein R¹-R⁴, A,X, Q and n are defined as above, with a nucleophilic compound of formulaXV

[0916]  wherein “Met” is a metal such as zinc or copper, carryingsuitable ligands chosen preferentially from trifluoro-methanesulfonate,halide or C₁-C₆ alkyl, to obtain a compound of formula (Ia) wherein n,Ar, R¹-R⁸, R⁷, A, X and 0 is defined as above except that R⁸ is not H,and Z is C.

[0917] j) saponification a compound of formula XVI

[0918]  wherein n, Ar, R¹-R⁸, A, X, Z and Q is defined as above exceptthat R⁸ is not H, to obtain a compound of formula (Ia) wherein n, Ar,R¹-R⁷, A, X, Z and Q is defined as above and wherein R⁸ is H.

[0919] The starting materials are commercially available or readilyprepared by methods familiar to those skilled in the art.

[0920] Pharmacological Methods

[0921] In vitro PPAR alpha and PPAR gamma activation activity.

[0922] Principle

[0923] The PPAR gene transcription activation assays were based ontransient transfection into human HEK293 cells of two plasmids encodinga chimeric test protein and a reporter protein respectively. Thechimeric test protein was a fusion of the DNA binding domain (DBD) fromthe yeast GAL4 transcription factor to the ligand binding domain (LBD)of the human PPAR proteins. The PPAR LBD harbored in addition to theligand binding pocket also the native activation domain (activatingfunction 2=AF2) allowing the fusion protein to function as a PPAR liganddependent transcription factor. The GAL4 DBD will force the fusionprotein to bind only to Gal4 enhancers (of which none existed in HEK293cells). The reporter plasmid contained a Gal4 enhancer driving theexpression of the firefly luciferase protein. After transfection, HEK293cells expressed the GAL4-DBD-PPAR-LBD fusion protein. The fusion proteinwill in turn bind to the Gal4 enhancer controlling the luciferaseexpression, and do nothing in the absence of ligand. Upon addition tothe cells of a PPAR ligand, luciferase protein will be produced inamounts corresponding to the activation of the PPAR protein. The amountof luciferase protein is measured by light emission after addition ofthe appropriate substrate.

[0924] Methods

[0925] Cell culture and transfection: HEK293 cells were grown inDMEM+10% FCS, 1% PS. Cells were seeded in 96-well plates the day beforetransfection to give a confluency of 80% at transfection. 0,8 μg DNA perwell was transfected using FuGene transfection reagent according to themanufacturers instructions (Boehringer-Mannheim). Cells were allowed toexpress protein for 48 h followed by addition of compound.

[0926] Plasmids: Human PPAR a and y was obtained by PCR amplificationusing cDNA templates from liver, intestine and adipose tissuerespectively. Amplified cDNAs were cloned into pCR2.1 and sequenced. TheLBD from each isoform PPAR was generated by PCR (PPARα: aa 167-C-term;PPARγ: aa 165- C-term) and fused to GAL4-DBD by subcloning fragments inframe into the vector pM1 generating the plasmids pM1αLBD and pM1γLBD.Ensuing fusions were verified by sequencing. The reporter wasconstructed by inserting an oligonucleotide encoding five repeats of theGal4 recognition sequence into the pGL2 vector (Promega).

[0927] Compounds: All compounds were dissolved in DMSO and diluted1:1000 upon addition to the cells. Cells were treated with compound(1:1000 in 200 μl growth medium including delipidated serum) for 24 hfollowed by luciferase assay.

[0928] Luciferase assay: Medium including test compound was aspiratedand 100 μl PBS incl. 1 mM Mg++ and Ca++ was added to each well. Theluciferase assay was performed using the LucLite kit according to themanufacturers instructions (Packard Instruments). Light emission wasquantified by counting SPC mode on a Packard Instruments top-counter.

[0929] Pharmaceutical Compositions

[0930] In another aspect, the present invention includes within itsscope pharmaceutical compositions comprising, as an active ingredient,at least one of the compounds of formula (Ia) or a pharmaceuticallyacceptable salt thereof together with a pharmaceutically acceptablecarrier or diluent.

[0931] Pharmaceutical compositions containing a compound of the presentinvention may be prepared by conventional techniques, e.g. as describedin Remington: The Science and Practise of Pharmacy, 19th Ed., 1995. Thecompositions may appear in conventional forms, for example capsules,tablets, aerosols, solutions, suspensions or topical applications.

[0932] Typical compositions include a compound of formula (Ia) or apharmaceutically acceptable acid addition salt thereof, associated witha pharmaceutically acceptable excipient which may be a carrier or adiluent or be diluted by a carrier, or enclosed within a carrier whichcan be in the form of a capsule, sachet, paper or other container. Inmaking the compositions, conventional techniques for the preparation ofpharmaceutical compositions may be used. For example, the activecompound will usually be mixed with a carrier, or diluted by a carrier,or enclosed within a carrier which may be in the form of a ampule,capsule, sachet, paper, or other container. When the carrier serves as adiluent, it may be solid, semi-solid, or liquid material which acts as avehicle, excipient, or medium for the active compound. The activecompound can be adsorbed on a granular solid container for example in asachet. Some examples of suitable carriers are water, salt solutions,alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil,peanut oil, olive oil, lactose, terra alba, sucrose, cyclodextrin,amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia,stearic acid or lower alkyl ethers of cellulose, silicic acid, fattyacids, fatty acid amines, fatty acid monoglycerides and diglycerides,pentaerythritol fatty acid esters, polyoxyethylene,hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrieror diluent may include any sustained release material known in the art,such as glyceryl monostearate or glyceryl distearate, alone or mixedwith a wax. The formulations may also include wetting agents,emulsifying and suspending agents, preserving agents, sweetening agentsor flavouring agents. The formulations of the invention may beformulated so as to provide quick, sustained, or delayed release of theactive ingredient after administration to the patient by employingprocedures well known in the art.

[0933] The pharmaceutical compositions can be sterilized and mixed, ifdesired, with auxiliary agents, emulsifiers, salt for influencingosmotic pressure, buffers and/or colouring substances and the like,which do not deleteriously react with the active compounds.

[0934] The route of administration may be any route, which effectivelytransports the active compound to the appropriate or desired site ofaction, such as oral, nasal, pulmonary, transdermal or parenteral e.g.rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular,intranasal, ophthalmic solution or an ointment, the oral route beingpreferred.

[0935] If a solid carrier is used for oral administration, thepreparation may be tabletted, placed in a hard gelatin capsule in powderor pellet form or it can be in the form of a troche or lozenge. If aliquid carrier is used, the preparation may be in the form of a syrup,emulsion, soft gelatin capsule or sterile injectable liquid such as anaqueous or non-aqueous liquid suspension or solution.

[0936] For nasal administration, the preparation may contain a compoundof formula (Ia) dissolved or suspended in a liquid carrier, inparticular an aqueous carrier, for aerosol application. The carrier maycontain additives such as solubilizing agents, e.g., propylene glycol,surfactants, absorption enhancers such as lecithin (phosphatidylcholine)or cyclodextrin, or preservatives such as parabens.

[0937] For parenteral application, particularly suitable are injectablesolutions or suspensions, preferably aqueous solutions with the activecompound dissolved in polyhydroxylated castor oil.

[0938] Tablets, dragees, or capsules having talc and/or a carbohydratecarrier or binder or the like are particularly suitable for oralapplication. Preferable carriers for tablets, dragees, or capsulesinclude lactose, corn starch, and/or potato starch. A syrup or elixircan be used in cases where a sweetened vehicle can be employed.

[0939] A typical tablet which may be prepared by conventional tablettingtechniques may contain:

[0940] Core: Active compound (as free compound or salt thereof) 5 mgColloidal silicon dioxide (AEROSIL) 1.5 mg Cellulose, microcryst.(AVICEL) 70 mg Modified cellulose gum (AC-DI-SOL) 7.5 mg Magnesiumstearate Ad.

[0941] Coating: HPMC approx.   9 mg *Mywacett 9-40 T approx. 0.9 mg

[0942] The compounds of the invention may be administered to a mammal,especially a human in need of such treatment, prevention, elimination,alleviation or amelioration of diseases related to the regulation ofblood sugar.

[0943] Such mammals include also animals, both domestic animals, e.g.household pets, and nondomestic animals such as wildlife.

[0944] The compounds of the invention are effective over a wide dosagerange. For example, in the treatment of adult humans, dosages from about0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per daymay be used. A most preferable dosage is about 0.1 mg to about 70 mg perday. In choosing a regimen for patients it may frequently be necessaryto begin with a dosage of from about 2 to about 70 mg per day and whenthe condition is under control to reduce the dosage as low as from about0.1 to about 10 mg per day. The exact dosage will depend upon the modeof administration, on the therapy desired, form in which administered,the subject to be treated and the body weight of the subject to betreated, and the preference and experience of the physician orveterinarian in charge.

[0945] Generally, the compounds of the present invention are dispensedin unit dosage form comprising from about 0.1 to about 100 mg of activeingredient together with a pharmaceutically acceptable carrier per unitdosage.

[0946] Usually, dosage forms suitable for oral, nasal, pulmonal ortransdermal administration comprise from about 0.001 mg to about 100 mg,preferably from about 0.01 mg to about 50 mg of the compounds of formula(Ia) admixed with a pharmaceutically acceptable carrier or diluent.

[0947] In a further aspect, the present invention relates to a method oftreating and/or preventing type I or type II diabetes.

[0948] In a still further aspect, the present invention relates to theuse of one or more compounds of formula (Ia) or pharmaceuticallyacceptable salts thereof for the preparation of a medicament for thetreatment and/or prevention of type I or type II diabetes.

[0949] Any novel feature or combination of features described herein isconsidered essential to this invention.

[0950] The invention will now be described in further detail withreference to the following examples. The examples are provided forillustrative purposes, and are not to be construed as limiting the scopeof the invention in any way.

EXAMPLE 1

[0951]

[0952]3-(4-[2-[5H-Dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester

[0953] a)

[0954] Dibenzosuberenol (2.08 g, 10 mmol) was dissolved in dry THF (20mL) at 0° C. Sodium hydride (1.0 g of 50% mineral oil dispersion, 20mmol) was added. After 10 min. tert-butylbromoacetate (4.0 g, 20.0 mmol)was added over a period of 20 min and then stirred for 1 h. The reactionmixture was quenched with water at 0° C. and the product extracted withethyl acetate. The combined extracts were dried (MgSO₄), andconcentrated in vacuo. The product was redissolved in ether (20 mL) andadded dropwise to an ether (15 mL) suspension of lithium aluminiumhydride (190 mg, 5.0 mmol). The reaction was stirred 16 h at roomtemperature, quenched with water. The ether solution was washed withwater, dried, and concentrated in vacuo to give 1.3 g (50%) of2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethanol.

[0955] b)

[0956] Under a nitrogen atmosphere,2-(5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethanol (400 mg, 1.6 mmol),tributylphosphine (480 mg, 2.4 mmol) and2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (380 mg, 1.6mmol) were successively dissolved in dry benzene (10 mL). Solidazodicarboxylic dipiperidine (ADDP) (480 mg, 2.4 mmol) was added understirring at 0° C. to the solution. After 10 min, the reaction mixturewas brought to room temperature and the stirring was continued for 2 h.The mixture was added water and the product extracted with ethylacetate. The combined organic phases was dried (MgSO₄), and concentratedin vacuo. The residue was purified chromatography eluting with ethylacetate/hexane (1:9) to give 350 mg (47%) of the title compound: MS 472(M⁺).

EXAMPLE 2

[0957]

[0958]3-(4-[2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester

[0959] a)

[0960] 6,11-Dihydrodibenzo[b,e]thiepin-11-ol (1.14 g, 5 mmol) wasdissolved in dry THF (25 mL) at 0° C. Sodium hydride (0.24 g of 50%mineral oil dispersion, 5 mmol) was added portionwise at 0° C. and thenrefluxed for 30 min. tert-Butylbromoacetate (980 mg, 5.0 mmol) in dryTHF (10 mL) was added over a period of 20 min followed by a 30 minreflux. The reaction mixture was quenched with water at 0° C. and theproduct extracted with ether. The combined extracts were dried (MgSO₄),and concentrated in vacuo. The product was redissolved in ether andadded dropwise to an ether (15 mL) suspension of lithium aluminiumhydride (190 mg, 5.0 mmol). The reaction was stirred 16 h at roomtemperature, quenched with water, cooled, and filtered through Decalit.The ether solution was washed with saturated NaCl, dried, and purifiedby chromatography eluting with ethyl acetate/dichloromethan (1:10) togive 850 mg (63%) of2-(6,11-dihydrodibenzo[b,e]thiepin-11-yloxy)-ethanol. ¹H NMR (300 MHz,CDCl₃) δ 3.55-3.70 (m, 2H), 3.75-3.85 (m, 2H), 4.00 (bs, 1H), 4.85 (bs,1H), 5.55 (bs, 1H), 7.03-7.13 (m, 3H), 7.13-7.48 (m, 5H).

[0961] b)

[0962] Under a nitrogen atmosphere,2-(6,11-dihydrodibenzo[b,e]thiepin-11-yloxy)-ethanol (340 mg, 1.25mmol), tributylphosphine (280 mg, 1.37 mmol) and2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (330 mg, 1.37mmol) were successively dissolved in dry benzene (10 mL). Solidazodicarboxylic dipiperidine (ADDP) (350 mg, 1.37 mmol) was added understirring at 0° C. to the solution. After 10 min, the reaction mixturewas brought to room temperature and the stirring was continued for 16 h.Heptane (10 mL) was added to the reaction mixture and dihydro-ADDPseparated out was filtered off. After evaporation of the solvent theproduct was purified chromatography eluting with ethyl acetate/heptane(1:4) to give 460 mg (75%) of the title compound: ¹H NMR (300 MHz,CDCl₃) δ 1.15 (t, 3H), 1.25 (t, 3H), 2.95 (d, 2H), 3.30-3.40 (m, 1H),3.55-3.65 (m, 1H), 2.85 (t, 2H), 3.95 (t, 1H), 4.10-4.22 (m, 4H),4.5-5.1 (bs, 1H), 5.60-5.75 (bs, 1H), 6.82 (d, 2H), 7.05-7.50 (m, 10H).

EXAMPLE 3

[0963]

[0964]3-(4-[2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid

[0965]3-(4-[2-(6,11-Dihydrodibenzo[b,e]thiepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester (example 2) (220 mg, 0.44 mmol) in ethanol (5 mL) wasadded NaOH 1 N (0.9 mL, 0.9 mmol). The mixture was stirred at roomtemperature for 16 h. The ethanol was evaporated of and pH adjusted withHCl 1 N to pH 1. After extraction with dichloromethane the product waspurified by chromatography, using dichloromethane/methanol (9:1) aseluent, to give 126 mg (62%) of the title compound: ¹H NMR (300 MHz,CDCl₃) δ1.15 (t, 3H), 2.85-3.10 (m, 2H), 3.32-3.42 (m, 1H), 3.52-3.65(m, 1H), 2.85 (t, 2H), 3.954.05 (m, 1H), 4.104.22 (m, 2H), 4.5-5.1 (bs,1H), 5.60-5.75 (bs, 1H), 6.82 (d, 2H), 7.05-7.50 (m, 10H).

EXAMPLE 4

[0966]

[0967]3-(4-[2-(6,11-Dihydrodibenzo[b,e]oxepin-11-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester

[0968] a)

[0969] 6,11-Dihydrodibenzo[b,e]oxepin-11-ol (1.06 g, 5 mmol) wasdissolved in dry THF (25 mL) at 0° C. Sodium hydride (0.24 g of 50%mineral oil dispersion, 5 mmol) was added portionwise at 0° C. and thenrefluxed for 30 min. tert-Butylbromoacetate (980 mg, 5.0 mmol) in dryTHF (10 mL) was added over a period of 20 and the mixture stirred at 35°C. for 16 h. The reaction mixture was quenched with water at 0° C. andthe product extracted with ether. The combined extracts were dried(MgSO₄), and concentrated in vacuo. The product was redissolved in etherand added dropwise to an ether (15 mL) suspension of lithium aluminiumhydride (190 mg, 5.0 mmol). The reaction was stirred 48 h at roomtemperature, quenched with water, cooled, and filtered through Decalit.The ether solution was washed with saturated NaCl, dried, and purifiedby chromatography eluting with ethyl acetate/dichloromethan (1:10) togive 267 mg (21%) of2-(6,11-dihydrodibenzo[b,e]oxepin-11-yloxy)-ethanol.

[0970] b)

[0971] Under a nitrogen atmosphere,2-(6,11-dihydrodibenzo[b,e]oxepin-11-yloxy)-ethanol (256 mg, 1.0 mmol),tributylphosphine (223 mg, 1.1 mmol) and2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (262 mg, 1.1mmol) were successively dissolved in dry benzene (10 mL). Solidazodicarboxylic dipiperidine (ADDP) (278 mg, 1.1 mmol) was added understirring at 0° C. to the solution. After 10 min, the reaction mixturewas brought to room temperature and the stirring was continued for 16 h.Heptane (10 mL) was added to the reaction mixture and dihydro-ADDPseparated out was filtered off. After evaporation of the solvent theproduct was purified chromatography eluting with ethyl acetate/heptane(1:4) to give 175 mg (37%) of the title compound: ¹H NMR (300 MHz,CDCl₃) δ 1.15 (t, 3H), 1.25 (t, 3H), 2.93 (d, 2H), 3.30-3.40 (m, 1H),3.55-3.65 (m, 1H), 3.65-3.75 (m, 1H), 3.78-3.88 (m, 1H), 3.95 (t, 1H),4.10 (t, 2H), 4.15 (q, 2H), 4.85 (d, 1H), 5.25 (s, 1H), 6.15 (d, 1H),6.75 (d, 2H), 6.85-6.95 (m, 2H), 7.10 (d, 2H), 7.15-7.40 (m, 6H).

EXAMPLE 5

[0972]

[0973]3-(4-[2-(2,10-Dichloro-12H-5,7-dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester

[0974] a)

[0975] To a solution of bis-(5-chloro-2-hydroxyphenyl)-methane (24.4 g,90.7 mmol) in dry DMF (340 mL) was added diiodomethane (25.5 g, 95.0mmol) and potassium carbonate (18.2 g, 132 mmol). The mixture wasstirred at 105° C. for 16 h. The mixture was added to ice water (1200mL) and stirred for 30 min. The product was isolated by filtration, andwashed with water and suspended in a mixture of ethanol (200 mL) and 4NNaOH (50 mL). The mixture was heated at 80° C. for 1 h. The mixture wasadded to water (600 mL) and 21.45 g (84%)2,10-dichloro-12H-dibenzo[d,g][1,3]-dioxocin was isolated by filtration.

[0976] b)

[0977] To a solution of 2,10-dichloro-12H-dibenzo[d,g][1,3]-dioxocin(21.4 g, 76.1 mmol) and N-bromosuccinimide (13.5 g, 76.1 mmol) intetrachloromethane (275 mL) was added azobisisobutyronitrile (200 mg,1.2 mmol). The mixture was heated at 80° C. for 24 h. Another 3×azobisisobutyronitrile (200 mg, 1.2 mmol) was added within the 24 h. Themixture was filtrated and the solution phase concentrated in vacuo. Theresidue was added dichloromethane (30 mL) and ether (100 mL). Themixture was filtered and the solution phase concentraded in vacuo. Theresidue was submitted to flash chromatography eluting with heptane/ethylacetate (3:1) to give 7.4 g (27%) of12-bromo-2,10-dichloro-12H-5,7-dioxa-dibenzo[a,d]cyclooctene.

[0978] c)

[0979] A mixture of12-bromo-2,10-dichloro-12H-5,7-dioxa-dibenzo[a,d]cyclooctene (900 mg,2.5 mmol), 2-bromoethanol (3.75 g, 30 mmol) and potassium carbonate (1.0g, 7.2 mmol) in dichloromethane (10 mL) was heated at 120° C. for 4 h.The reaction mixture was concentrated in vacuo, added water (25 mL) andthe product extracted with ethyl acetate (3×25 mL). The combined organicphases were dried (MgSO₄), filtered and evaporated to give 832 mg (82%)of12-(2-bromo-ethoxy)-2,10-dichloro-12H-5,7-dioxa-dibenzo[a,d]cyclooctene.

[0980] d)

[0981] To a solution of12-(2-bromo-ethoxy)-2,10-dichloro-12H-5,7-dioxa-dibenzo[a,d]cyclooctene(404 mg, 1.0 mmol) and 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acidethyl ester (238 mg, 1.0 mmol) in dry toluene (6 mL) was added potassiumcarbonate (276 mg, 2.0 mmol) and 18-crown-6 (528 mg, 2.0 mmol). Themixture was heated at 60° C. for 16 h. The mixture was filtered, andconcentrated in vacuo. The residue was submitted to flash chromatographyusing toluene/ethyl acetate (19:1) as eluent to give 297 mg (53%) of thetitle compound;

[0982]¹H NMR (300 MHz, CDCl₃) δ 1.18 (t, 3H), 1.25 (t, 3H), 2.96 (d,2H), 3.30-3.42 (m, 1H), 3.55-3.65 (m, 1H), 3.90-3.95 (m, 2H), 4.0 (t,1H), 4.15-4.25 (m, 4H), 4.55 (d, 1H), 5.87 (d, 1H), 6.18 (s, 1H),6.88-6.95 (m, 4H), 7.10-7.25 (m, 4H), 7.60 (d, 2H).

EXAMPLE 6

[0983]

[0984]3-(4-[2-(2,10-Dichloro-12H-5,7-dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid

[0985]3-(4-[2-(2,10-Dichloro-12H-5,7-dioxa-dibenzo[a,d]cycloocten-12-yloxy)-ethoxy]-phenyl)-2-ethoxy-propionicacid ethyl ester (example 5) (450 mg, 0.8 mmol) in ethanol (8 mL) wasadded NaOH 1 N (4.0 mL, 4.0 mmol). The mixture was stirred at roomtemperature for 16 h. The sodium salt of the title compound was isolatedby filtration and washed with ethanol/water to give 272 mg (61%): m.p.240-241-C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.95 (t, 3H), 2.55-2.65 (m, 1H),2.80-2.88 (m, 1H), 3.05-3.15 (m, 1H), 3.48-3.60 (m, 2H), 3.80-3.90 (m,2H), 4.15-4.25 (m, 2H), 4.65 (d, 1H), 5.90 (d, 1H), 6.13 (s, 1H), 6.85(d, 2H), 7.05 (d, 2H), 7.15 (d, 2H), 7.23-7.30 (m, 2H), 7.55-7.58 (m,2H).

EXAMPLE 7

[0986]

[0987]2-Ethoxy-3-(4-[2-(2-methyl-9,10-dihydro-4H-1-oxa-3-aza-benzo[f]azulen-4-yloxy)-ethoxy]-phenyl)-propionicacid ethyl ester

[0988] a)

[0989] To a ice cooled solution of oxazol (1.08 g, 5.0 mmol) in dry THF(50 mL) was added sodium hydride (500 mg of 60% mineral oil dispersion,10 mmol). After stirring for 20 min. tert-butyl bromoacetate (1.95 g, 10mmol) was added. Stirring at room temperature for 1 h. The reactionmixture was quenched with water and the product extracted with ethylacetate (2×50 mL). The combined organic phases were dried (MgSO₄),filtered and concentrated in vacuo to give 1.47 g (90%) of(2-methyl-9,10-dihydro-4H-1-oxa-3-aza-benzo[f]azulen-4-yloxy)-aceticacid tert-butyl ester.

[0990] b)

[0991] To a solution of(2-methyl-9,10-dihydro-4H-1-oxa-3-aza-benzo[f]azulen-4-yloxy)-aceticacid tert-butyl ester (1.4 g, 4.3 mmol) in dry ether (10 mL) was added asuspension of lithium aluminum hydride (245 mg, 6.5 mmol) in dry ether(40 mL). Stirring at room temperature for 1.5 h. The reaction wasquenched with water an the product extracted with ether. The combinedether phases were dried MgSO₄, filtered and concentrated in vacuo togive 900 mg (91%) of2-(2-methyl-9,10-dihydro-4H-1-oxa-3-aza-benzo[f]azulen-4-yloxy)-ethanol.

[0992] c)

[0993] Under a nitrogen atmosphere,2-(2-methyl-9,10-dihydro-4H-1-oxa-3-aza-benzo[f]azulen-4-yloxy)-ethanol(400 mg, 1.6 mmol), tributylphosphine (480 mg, 2.4 mmol) and2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (380 mg, 1.6mmol) were successively dissolved in dry benzene (10 mL). Solidazodicarboxylic dipiperidine (ADDP) (480 mg, 2.4 mmol) was added understirring at 0° C. to the solution. After 10 min, the reaction mixturewas brought to room temperature and the stirring was continued for 16 h.The mixture was added water and the product extracted with ethylacetate. The combined organic phases was dried (MgSO₄), and concentratedin vacuo. The residue was purified chromatography eluting with petroleumether/ethyl acetate (1:1) to give 300 mg (40%) of the title compound: ¹HNMR (300 MHz, CDCl₃) δ 1.15 (t, 3H). 1.20 (t, 3H), 22.38 (s, 3H),2.60-2.85 (m, 2H), 2.90-3.05 (m, 3H), 3.25-3.38 (m, 1H), 3.52-3.65 (m,1H), 3.65-3.75 (m, 1H). 3.75-3.90 (m, 2H), 3.95 (t, 1H), 4.05 (t, 2H),4.15 (q, 2H), 5.25 (s, 1H), 6.75 (d, 2H), 7.10 (d, 2H), 7.13-7.30 (m,4H).

EXAMPLE 8

[0994]

[0995]3-(4-[2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propanoicacid ethyl ester

[0996] A mixture of5-(3-mesyloxypropylidene)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten (5.0g, 15.2 mmol), ethyl 3-(4-hydroxyphenyl)-2-ethoxypropanoate (3.7 g, 15.5mmol), potassium carbonate (2.9 g, 21 mmol) and dimethylformamide (10ml) was heated at 100° C. for 5 h. Benzene (200 ml) and water (200 ml)were added and the phases were separated. The organic phase was driedand the solvent evaporated in vacuo. The residue was purified bychromatography on silica gel eluting with benzene/chloroform, to givefirst 2.5 g of 5-propenylidene-10,11-dihydro-5H-dibenzo(a,d)cycloheptenand then 1.5 g (21%) of the title compound as an oil. ¹H NMR (250 MHz,CDCl₃) δ 7.10-7.35 (m, 10H); 6.85 (d, 2H); 6.06 (t, 1H); 4.27 (q, 2H);4.07 (m, 3H); 3.68 (m, 1H); 3.45 (m, 1H); 3.17 (bs, 4H); 3.06 (d, 2H);2.69 (q, 2H); 1.27 (t, 3H); 0.99 (t, 3H).

EXAMPLE 9

[0997]

[0998]3-(4-[2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propanoicacid

[0999]3-(4-[2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-ethoxy]-phenyl)-2-ethoxy-propanoicacid ethyl ester (example 8) (1.5 g, 3.2 mmol) was dissolved in ethanol(30 ml) and 20% sodium hydroxide (3 ml) was added. After 3 days ethanolwas evaporated in vacuo, water (50 ml) and hydrochloric acid (2 ml) wereadded and the mixture was extracted with dichloromethane. The organicphase was dried (MgSO₄) and the solvent evaporated in vacuo. The residue(1.1 g, 78%) was dissolved in ethanol and treated with (L)-lysinemonohydrate (0.41 g). Ethanol was evaporated and the residue trituratedwith diethyl ether. The crystalline product was filtered off and driedin the air. This afforded 1.45 g of the title compound as salt with(L)-lysine (dihydrate). M.p. 148-150° C. ¹H NMR (250 MHz, DMSO-d₆ δ7.00-7.35 (m, 10H); 6.75 (bd, J=8.2 Hz, 2H); 6.26 (bs, 8H); 5.91 (t,J=6.6 Hz, 1H); 4.02 (t, J=6.2 Hz, 2H); 3.76 (m, 1H); 3.59 (m)+3.31 (m),2H; 3.07 (bs (4H); 2.70-2,95 (m, 4H); 2.51 (bq, 2H); 1.66 (bm, 6H); 1.03(t, J=7.2 Hz, 3H).

EXAMPLE 10

[1000]

[1001]3-(4-[2-([10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl]-methyl-amino)-ethoxy]-phenyl)-2-ethoxypropanoicacid ethyl ester

[1002] A mixture of5-(methylamino)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene hydrochloride(1.8 g, 6.94 mmol), ethyl 3-(4-bromethoxyphenyl)-2-ethoxypropanoate (2.4g, 6.95 mmol), potassium carbonate (2.9 g, 21 mmol) anddimethylformamide (7 ml) was heated at 100° C. for 5 h. Benzene (200 ml)and water (200 ml) were added and the phases were separated. The organicphase was dried and the solvent evaporated in vacuo. The residue waspurified by chromatography on silica gel eluting with benzene/chloroformto give 2.2 g (65%) of the title compound as an oil. RF=0.60(chloroform/ethanol/ammonia=20:2:0.1)

EXAMPLE 11

[1003]

[1004]3-(4-[2-([10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl]-methyl-amino)-ethoxy]-phenyl)-2-ethoxypropanoicacid

[1005]3-(4-[2-([10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl]-methyl-amino)-ethoxy]-phenyl)-2-ethoxypropanoicacid ethyl ester (example 10)(1.5 g, 3.07 mmol) was dissolved in ethanol(20 ml) and 20% sodium hydroxide (2 ml) was added. After 6 days ethanolwas evaporated in vacuo, water (50 ml) and acetic acid (2 ml) were addedand the mixture was extracted with dichloromethane. The organic phasewas dried (MgSO₄) and the solvent evaporated in vacuo. The residue (1.4g) was dissolved in acetone and neutralized with solution of hydrogenchloride in diethyl ether. The solvents were evaporated and the residuewas triturated with diethyl ether yielding 1.15 g (74%) of the titlecompound as amorphous solid (hemihydrate). ¹H NMR (250 MHz, DMSO-d₆) δ10.50 (bs, 1H); 7.60 (bs)+7.10-7.50 (m, 10H), 6.87 (d, J=7.9 Hz, 2H),5.84 (bd, J=7.0 Hz, 1H), 4.49 (bs, 2H), 4.00 (t, J=5.6 Hz; +bm, 3H),3.30-3,60 (m+m, 4H), 2.80-3.10 (s+bm, 7H), 1.07 (t, J=7.2 Hz, 3H).

What is claimed is:
 1. A compound of formula (Ia)

wherein R¹, R², R³, and R⁴ independently of each other representhydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, orC₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂alkoxy,aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl,heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy,hydroxyC₁₋₁₂alkyl, amino, acylamino, C₁₋₁₂alkyl-amino, arylamino,aralkylamino, aminoC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl,aralkoxycarbonyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl,aralkoxyC₁₋₁₂alkyl, C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,—COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹² independently of each other areselected from hydroxy, halogen, perhalomethyl, C₁₋₆-alkoxy or aminooptionally substituted with one or more C₁₋₆-alkyl, perhalomethyl oraryl; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano; or R¹ and R², R² and R³ and/or R³ and R⁴,together with the carbon atoms to which they are attached, may form acyclic ring containing from 5 to 7 carbon atoms optionally substitutedwith one or more C₁₋₆-alkyl; ring A represents a 5-6 membered cyclicring, optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro, cyano, formyl, or C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl,C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂alkoxy, aryl, aryloxy, aralkyl,aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy,heteroaralkoxy, acyl, acyloxy, hydroxyC₁₋₁₂alkyl, amino, acylamino,C₁₋₁₂alkyl-amino, arylamino, aralkylamino, aminoC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl, aralkoxyC₁₋₁₂alkyl,C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonylamino,aryloxycarbonylamino, aralkoxycarbonylamino, —COR¹¹, or —SO₂R¹², whereinR¹¹ and R¹² independently of each other are selected from hydroxy,halogen, perhalomethyl, C₁₋₆-alkoxy or amino optionally substituted withone or more C₁₋₆-alkyl, perhalomethyl or aryl; optionally substitutedwith one or more halogen, perhalomethyl, hydroxy, nitro or cyano; X is—O—, —(NR⁹)—CH₂—, —(C═O)—, —(NR⁹)—S(O₂)—, —(NR⁹)—, —(CO)—(CHR⁹)—, —S—,—(SO)—, —(SO₂)—, —CH₂—O—CH₂—, wherein R⁹ is hydrogen, halogen, hydroxy,nitro, cyano, formyl, C₁₋₁₂alkyl, C₁₋₁₂alkoxy, aryl, aryloxy, aralkyl,aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy,heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino,C₁₋₁₂alkyl-amino, arylamino, aralkylamino, aminoC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl, aralkoxyC₁₋₁₂alkyl,C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonylamino,aryloxycarbonylamino, aralkoxycarbonylamino, —COR¹³, or —SO₂R¹⁴, whereinR¹³ and R¹⁴ independently of each other are selected from hydroxy,halogen, C₁₋₆-alkoxy, amino optionally substituted with one or moreC₁₋₆-alkyl, perhalomethyl or aryl; Z is —CH₂—, —O—, —S—, >SO_(2,),>NR¹⁵, wherein R¹⁵ is hydrogen, halogen, hydroxy, nitro, cyano, formyl,C₁₋₁₂alkyl, C₁₋₁₂alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl,heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy,hydroxyalkyl, amino, acylamino, C₁₋₁₂alkyl-amino, arylamino,aralkylamino, aminoC₁₋₁₂alkyl, C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl,aralkoxycarbonyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₁₂alkyl,aralkoxyC₁₋₁₂alkyl, C₁₋₁₂alkylthio, thioC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino,—COR¹⁶, or —SO₂R¹⁷, wherein R¹⁵ and R¹⁷ independently of each other areselected from hydroxy, halogen, C₁₋₆-alkoxy, amino optionallysubstituted with one or more C₁₋₆-alkyl, perhalomethyl or aryl; Q is—O—, —S—, >NR¹⁸ wherein R¹⁸ is hydrogen or C₁₋₆-alkyl; Ar representsarylene, heteroarylene, or a divalent heterocyclic group optionallysubstituted with one or more C₁₋₆-alkyl or aryl; R⁵ represents hydrogen,hydroxy, halogen, C₁₋₁₂alkoxy, C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl,C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl or aralkyl; optionally substituted with oneor more halogen, perhalomethyl, hydroxy, nitro or cyano; or R⁵ forms abond together with R⁶; R⁶ represents hydrogen, hydroxy, halogen,C₁₋₁₂alkoxy, C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl,acyl or aralkyl; optionally substituted with one or more halogen,perhalomethyl, hydroxy, nitro or cyano; or R⁶ forms a bond together withR⁵; R⁷ represents hydrogen, C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl,C₂₋₁₂-alkynyl, aryl, aralkyl, C₁₋₁₂alkoxyC₁₋₁₂alkyl,C₁₋₁₂alkoxycarbonyl, aryloxycarbonyl, C₁₋₁₂alkylaminocarbonyl,arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkylgroups; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano; R⁸ represents hydrogen, C₁₋₁₂alkyl,C₄₋₁₂-alkenynyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, aryl, aralkyl,heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substitutedwith one or more halogen, perhalomethyl, hydroxy, nitro or cyano; Yrepresents oxygen, sulphur or NR¹⁰, where R¹⁰ represents hydrogen,C₁₋₁₂alkyl, aryl, hydroxyC₁₋₁₂alkyl or aralkyl groups or when Y is NR¹⁰,R⁸ and R¹⁰ may form a 5 or 6 membered nitrogen containing ring,optionally substituted with one or more C₁₋₆alkyl; n is an integerranging from 1 to 4; or a pharmaceutically acceptable salt thereof.
 2. Acompound of claim 1 wherein R¹, R², R³, and R⁴ independently of eachother represent hydrogen, halogen, perhalomethyl, hydroxy, cyano, orC₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl,aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC₁₋₇alkyl, amino,acylamino, C₁₋₇alkylamino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio,thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino,aralkoxycarbonylamino, —COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹²independently of each other are selected from hydroxy, perhalomethyl,C₁₋₆-alkoxy or amino optionally substituted with one or more C₁-alkyl,perhalomethyl or aryl; optionally substituted with one or more halogen,perhalomethyl, hydroxy, nitro or cyano; or R¹ and R², R² and R³ and/orR³ and R⁴ may form a cyclic ring containing from 5 to 7 carbon atomsoptionally substituted with one or more C₁₋₆alkyl.
 3. A compound ofclaim 1 wherein R¹, R², R³, and R⁴ independently of each other representhydrogen, halogen, perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl,C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy,aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,heteroaryloxy, heteroaralkoxy, acyl, hydroxyC₁₋₇alkyl, amino, acylamino,C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio,thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino oraralkoxycarbonylamino.
 4. A compound of claim 1 wherein R¹, R², R³, andR⁴ independently of each other represent hydrogen, halogen,perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl,C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl,aralkoxy, acyl, hydroxyC₁₋₇alkyl, amino, C₁₋₇alkyl-amino, arylamino,aralkylamino, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alky orC₁₋₇alkylthio.
 5. A compound of claim 1 wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, halogen, perhalomethyl,or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl,hydroxyC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl oraralkoxyC₁₋₇alkyl.
 6. A compound of claim 1 wherein R¹, R², R³, and R⁴independently of each other represent hydrogen, halogen or C₁₋₇alkyl. 7.A compound of claim 1 wherein R¹, R², R³, and R⁴ independently of eachother represent hydrogen, chlorine or methyl.
 8. A compound of claim 1wherein ring A represents a 5-6 membered cyclic ring, optionallysubstituted with one or more halogen, perhalomethyl, hydroxy, cyano orC₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl,aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC₁₋₇alkyl, amino,acylamino, C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio,thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino,aralkoxycarbonylamino, —COR¹¹, or —SO₂R¹², wherein R¹¹ and R¹²independently of each other are selected from hydroxy, perhalomethyl,C₁₋₆-alkoxy or amino optionally substituted with one or more C₁₋₆-alkyl,perhalomethyl or aryl; optionally substituted with one or more halogen,perhalomethyl, hydroxy or cyano.
 9. A compound of claim 1 wherein ring Arepresents a 5-6 membered cyclic ring, optionally substituted with oneor more halogen, perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl,C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy,aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl,heteroaryloxy, heteroaralkoxy, acyl, hydroxyC₁₋₇alkyl, amino, acylamino,C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio,thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino oraralkoxycarbonylamino.
 10. A compound of claim 1 wherein ring Arepresents a 5-6 membered cyclic ring, optionally substituted with oneor more halogen, perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl,C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy,aralkyl, aralkoxy, acyl, hydroxyC₁₋₇alkyl, amino, C₁₋₇alkyl-amino,arylamino, aralkylamino, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl,aralkoxyC₁₋₇alkyl or C₁₋₇alkylthio.
 11. A compound of claim 1 whereinring A represents a 5-6 membered cyclic ring, optionally substitutedwith one or more halogen, perhalomethyl or C₁₋₇alkyl, C₄₋₇-alkenynyl,C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aralkyl, hydroxyC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl or aralkoxyC₁₋₇alkyl.
 12. Acompound of claim 1 wherein ring A represents a 5-6 membered cyclicring, optionally substituted with one or more chlorine or methyl groups.13. A compound of claim 1 wherein X is —O—, —(NR⁹)—CH₂—, —(C═O)—,—(NR⁹)—S(O₂)—, —(NR⁹)—, —(CO)—(CHR⁹)—, —S—, —(SO)—, —(SO₂)—, or—CH₂—O—CH₂—, wherein R⁹ is hydrogen, halogen, hydroxy, C₁₋₇alkyl,C₁₋₇alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl,heteroaralkyl, heteroaryloxy, heteroaralkoxy, hydroxyalkyl, amino,acylamino, C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl,C₁₋₇alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl,C₁₋₁₂alkylthio, thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino,aryloxycarbonylamino or aralkoxycarbonylamino.
 14. A compound of claim 1wherein X is —O—, —(NR⁹)—CH₂—, —(C═O)—, —(NR⁹)—S(O₂)—, —(NR⁹)—,—(CO)—(CHR⁹)—, —S—, —(SO)—, —(SO₂)—, or —CH₂—O—CH₂—, wherein R⁹ ishydrogen, halogen, hydroxy, C₁₋₇alkyl, aryl, aralkyl,C₁₋₇alkoxyC₁₋₁₂alkyl, aryloxyC₁₋₇alkyl or aralkoxyC₁₋₇alkyl.
 15. Acompound of claim 1 wherein X is —O—, —(NR⁹)—CH₂—, —(C═O)—,—(NR⁹)—S(O₂)—, —(NR⁹)—, —(CO)—(CHR⁹)—, —S—, —(SO)—, —(SO₂)—, or—CH₂—O—CH₂—, wherein R⁹ is hydrogen.
 16. A compound of claim 1 wherein Zis —CH₂—, —O—, —S—, >NR¹⁵, wherein R¹⁵ is hydrogen, C₁₋₁₂alkyl,C₁₋₇alkoxy, aralkyl, aralkoxy, hydroxyalkyl, aminoC₁₋₇alkyl,C₁₋₁₂alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl or aralkoxyC₁₋₇alkyl.
 17. Acompound of claim 1 wherein Z is —CH₂—, —O—, —S— or >NR¹⁵, wherein R¹⁵is hydrogen.
 18. A compound of claim 1 wherein Z is —O—.
 19. A compoundof claim 1 wherein Q is —O—, —S— or >NR¹⁸ wherein R¹⁸ is hydrogen ormethyl.
 20. A compound of claim 1 wherein Q is —O— or >NR¹⁸ wherein R¹⁸is methyl.
 21. A compound of claim 1 wherein Ar represents aryleneoptionally substituted with one or more C₁₋₆-alkyl or aryl.
 22. Acompound of claim 1 wherein Ar is phenyl.
 23. A compound of claim 1wherein R⁵ is hydrogen, hydroxy, halogen, C₁₋₇alkoxy, C₁₋₇alkyl,C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl or aralkyl, or R⁵ forms abond together with R⁶.
 24. A compound of claim 1 wherein R⁵ is hydrogenor R⁵ forms a bond together with R⁶.
 25. A compound of claim 1 whereinR⁵ is hydrogen, hydroxy, halogen, C₁₋₇alkoxy, C₁₋₇alkyl, C₄₋₇-alkenynyl,C₂₋₇-alkenyl, C₂₋₇-alkynyl or aralkyl, or R⁵ forms a bond together withR⁶.
 26. A compound of claim 1 wherein R⁵ is hydrogen or R⁵ forms a bondtogether with R⁶.
 27. A compound of claim 1 wherein R⁷ is hydrogen,C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl,C₁₋₇alkoxyC₁₋₇alkyl, C₁₋₇alkoxycarbonyl, aryloxycarbonyl,C₁₋₇alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl,heteroaryl or heteroaralkyl.
 28. A compound of claim 1 wherein R⁷ ishydrogen, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl or C₂₋₇-alkynyl.
 29. Acompound of claim 1 wherein R⁷ is C₁₋₂alkyl.
 30. A compound of claim 1wherein R⁸ is hydrogen, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl,C₂₋₇-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkylgroups; optionally substituted with one or more halogen, perhalomethyl,hydroxy, nitro or cyano.
 31. A compound of claim 1 wherein R⁸ ishydrogen, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl oraralkyl.
 32. A compound of claim 1 wherein R⁸ is hydrogen or C₁₋₂alkyl.33. A compound of claim 1 wherein Y is oxygen, sulphur or NR¹⁰, whereR¹⁰ is hydrogen, C₁₋₇alkyl, aryl, hydroxyC₁₋₇alkyl or aralkyl.
 34. Acompound of claim 1 wherein Y is oxygen.
 35. A compound of claim 1wherein n is an integer ranging from 2 to
 3. 36. A compound of claim 1wherein A is benzo.
 37. A compound of claim 1 wherein A is a fivemembered ring containing S.
 38. A compound of claim 1 wherein Q is —O—.39. A compound of claim 1 wherein Q is —S—.
 40. A compound of claim 1wherein Q is >NR¹⁸, wherein R¹⁸ is C₁₋₆-alkyl.
 41. A compound of claim 1wherein Z is —O—.
 42. A compound of claim 1 wherein n is
 2. 43. Acompound of claim 1 wherein Q is —O—.
 44. A compound of claim 1 whereinAr is phenylene.
 45. A compound of claim 1 wherein R⁵ is H.
 46. Acompound of claim 1 wherein R⁶ is H.
 47. A compound of claim 1 whereinR⁷ is ethyl.
 48. A compound of claim 1 wherein R⁸ is H.
 49. Apharmaceutical composition comprising, as an active ingredient, aneffective amount of a compound of claim 1 together with apharmaceutically acceptable carrier or diluent.
 50. The pharmaceuticalcomposition of claim 49 in unit dosage form, comprising from about 0.05to about 100 mg of the compound.
 51. The pharmaceutical composition ofclaim 49 wherein the route of administration is oral, nasal,transdermal, pulmonal, or parenteral.
 52. A method of treating orpreventing conditions mediated the Peroxisome Proliferator-ActivatedReceptors (PPAR), the method comprising administering to a subject inneed thereof an effective amount of a compound of claim
 1. 53. A methodof treating or preventing diabetes or obesity, the method comprisingadministering to a subject in need thereof an effective amount of acompound of claim
 1. 54. The method of claim 52, wherein the effectiveamount of the compound is in the range of from about 0.05 to about 100mg per day.